gsk corporate responsibility reportintroduction introduction contribution society report ceo chairmans letter managing corporate responsibility cr important gsk cr governance cr principles stakeholder engagement stakeholder feedback responding government external affairs membership trade associations us lobbying expenditures political donations position key issues patient advocacy access medicine research ethical conduct employment practices human rights environment community investment data summary gsk corporate responsibility report introduction welcome gsks corporate responsibility report report explains approach wide range social ethical environmental issues associated business reports performance full webbased report available wwwgskcom gsk researchbased pharmaceutical company operations countries make prescription medicines vaccines overthecounter medicines consumer healthcare products business accounts worlds pharmaceutical market strong positions several therapeutic areas including antiinfectives asthma cancer cardiovascular depression diabetes hivaids urology overview business see annual report contribution society report explains approach significant corporate responsibility issues business including last years medicines vaccines transformed millions lives helped increase access medicines make medicines life expectancy lowered death rates conditions accessible poor patients developed developing heart disease stroke cancer medicines enable countries many people chronic diseases enjoy good health research development maintain high lead full lives developed countries healthcare ethical standards research publication advances mean people longer risk research results diseases polio tb major threats less century ago sales marketing maintain high ethical standards sales marketing products continued research development new medicines vital still many serious illnesses also covers employment practices approach treatments treatments may human rights environmental performance improved community investment discovering developing new medicines expensive average cost around million takes report average years society relies report covers corporate responsibility activity pharmaceutical industry fund research performance updates last corporate indeed majority medicines used around world responsibility report published march data relate developed pharmaceutical industry calendar year except stated gsk invested billion rd employs environmental data collected people prescription medicines pharmaceutical consumer manufacturing sites vaccines clinical development biologicals manufacturing sites believe business makes valuable pharmaceutical consumer rd sites well contribution society developing marketing distribution centres major office locations medicines improve peoples lives however smaller office sales locations include data recognise research development manufacture sites operation part year sale medicines raise ethical issues notes attached charts explain scope data stakeholders listen concerns address collection process parameter detail unless specified per unit sales figures absolute numbers ie total consumption energy water etc data environment health safety sections report externally verified gsk corporate responsibility report introduction continued scope data relates worldwide operations except indicated use external guidelines frameworks inform reporting relevant base report global reporting initiative guidelines included gri index website show elements guidelines cover aid comparison company reports number changes made years report response feedback received added summary give readers overview approach cr key issues business last year organized report according ten cr principles year still reporting progress principles reorganized sections make report easier navigate information marketing practices previously contained products customers incorporated ethical conduct section information previously contained leadership advocacy section embedded report particular government external affairs public private partnerships major public health initiatives information stakeholder engagement process see stakeholder engagement gsk corporate responsibility report ceo chairmans letter corporate responsibility fundamental delivering business goals interests shareholders remain paramount also need respond stakeholder expectations helping address societys healthcare challenges accept challenge solving problems healthcare provision developing world job one company alone however important contribution make access medicine programmes hivaids work world health organization eradicate lymphatic filariasis lf evidence efforts making shipped million preferentially priced combivir epivir tablets developing countries treatment hivaids donated million albendazole tablets prevention lf public private partnerships developing first pipeline new tuberculosis treatments years testing new vaccines treatments malaria disease takes devastating toll people africa corporate responsibility encompasses address manage issues arise business activities good performance corporate responsibility supports business strategy protects enhances relationships reputation doctors governments patients gsks core business research production medicines makes valuable contribution society many people medicines quite literally lifesaving satisfaction mean ignore issues associated research manufacture sale medicines publication research results marketing practices pharmaceutical sales representatives use animals research environmental impacts manufacturing processes confident right policies programmes place operate highest standards report provides update progress made ten corporate responsibility principles particular highlights include new policies authorship research articles consumer advertising patient advocacy clinical trial register contains results gsk sponsored clinical trials seek views wide range stakeholders respond suggestions possible report contains new information number areas response feedback received see stakeholder engagement hope report provides information seeking corporate responsibility gsk welcome feedback sir christopher gent jp garnier chairman chief executive officer gsk corporate responsibility report managing corporate responsibility corporate responsibility supports business strategy preparing us meet future expectations protecting reputation helping us reduce business risk important management cr issues integrated daytoday operations approach cr informed frequent discussions range stakeholders including employees shareholders patients doctors governments ngos information engagement process feedback received see stakeholder engagement government external affairs corporate responsibility cr governance important gsk gsks corporate responsibility committee consists non achieve business goals gsk focuses number executive directors provides boardlevel forum business drivers reviewing external issues potential impact gsks business reputation provides highlevel build best product pipeline industry guidance approach cr issues members benefit patients consumers society corporate executive team including ceo also continuously improve performance commercial attend crc meetings operational excellence committee meets four times year review improve access medicines range policies progress cr principles policies extensive programmes developed activities relating four principles access developing world medicines standards ethical conduct research innovation global community partnerships best place best people best reviewed annually principles discussed regularly work least every three years committees findings corporate responsibility encompasses achieve reported board goals implement business drivers means committee met four times reviewed operating way reflects values cr supports activity number areas including business success reducing business risks protecting reputation access medicines way conduct business affects relationship animal testing patients consumers use products clinical trials developing countries doctors prescribe medicines community partnerships governments regulate industry reputation people trust place products corporate responsibility reporting including final sign critical business cr report demonstrating stakeholders meet high reputation management ethical standards aspects work management significant business risks coordinated committed helping address healthcare challenges risk oversight compliance council rocc maintain support retain licence rocc also considers reputational corporate operate reputation standards operate responsibility risks employment practices also impact ability background information crc rocc attract retain motivate best people see risk management compliance gskcom business strategy see annual report gsk corporate responsibility report managing corporate responsibility continued management structure believe daytoday glaxosmithkline management cr issues performance done effectively within business operations experts cr issues work gsk cr ceo committee board coordination provided crossfunctional team made representatives key business areas representatives senior corporate cr managers direct access executive strategy appropriate executive team team reporting member role oversee development implementation communication cr policy across gsk ensures comprehensive consistent approach taken throughout organisation also small cr team coordinates policy development reporting communication access stakeholder community environment advocacy socially responsible investment medicines engagement investment analysts details environment health products emloyment human research ethics safety management see ehs customers practices rights innovation integrity management gsks cr committee sir christopher gent sir ian prosser dr lucy shapiro chairman cr committee sir ian formerly nonexecutive dr shapiro ludwig professor sir christopher former chief director smithkline beecham plc cancer research department executive officer vodafone chairman chief developmental biology group plc nonexecutive executive bass plc latterly director beckman center director lehman brothers intercontinental hotels molecular genetic medicine holdings inc director chairman world travel stanford university school international advisory board tourism council nonexecutive medicine holds phd hakluyt co senior deputy chairman bp plc molecular biology albert adviser bain co nonexecutive director sara lee einstein college medicine corporation also member cbi president 's committee gsk corporate responsibility report managing corporate responsibility continued cr principles community investment corporate responsibility statement principles make positive contribution communities identify key corporate responsibility issues operate invest health provide guidance employees standards education programmes partnerships aim bring company committed sustainable improvements underserved people developed developing world corporate responsibility statement engagement stakeholders principles want understand concerns mission business improve quality interest corporate responsibility issues engage human life enable people feel better range stakeholders communicate openly live longer focuses needs patients addressing cr issues ways aim achieve mission products activities meet needs different groups allowing us enhancing contribution make society pursue legitimate business goals sustaining economic performance operating environmentally responsible manner standards ethical conduct expect employees meet high ethical standards employment practices aspects business conducting activities treat employees respect dignity honesty integrity adhering cr principles encourage diversity ensure fair treatment complying applicable laws regulations phases employment provide safe healthy working environment support employees perform research innovation full potential take responsibility undertaking research innovating performance reputation business may explore apply new technologies human rights constructively engage stakeholders concerns committed upholding un universal may arise declaration human rights oecd guidelines ensure products subject rigorous mnes core labour standards set scientific evaluation testing safety effectiveness international labour organisation expect quality standards suppliers contractors business partners working gsks behalf comply exceed regulations legal standards applicable research development access medicines products continue research develop medicines products customers treat diseases developing world find sustainable ways improve access medicines promote products line high ethical disadvantaged people seek partnerships medical scientific standards comply support activity applicable laws regulations leadership advocacy caring environment establish challenging standards operate environmentally responsible manner corporate responsibility appropriate complexities systematic management environmental specific needs business building external impacts measurement performance setting guidelines experience share best practice challenging performance targets improve seek influence others remaining competitive efficiency activities minimise material order sustain business energy use waste generated aim find opportunities use renewable materials recycle waste gsk corporate responsibility report managing corporate responsibility continued stakeholder engagement stakeholder feedback engaging different groups interest section summarises feedback corporate way operate important part responsible responsibility cr performance reporting business practice stakeholders include employees cr opinion leaders sri investors employees investors patients doctors governments ngos cr opinion leader survey multilateral organisations local communities suppliers cr opinion leader survey sought views scientific community listening people cr performance reporting open views actions build telephone interviews survey provided indepth trust address concerns qualitative feedback designed produce discussion takes place normal course statistics second year commissioned business example scientists meet regularly survey nineteen participants also took academics researchers pharmaceutical part survey survey conducted companies access medicine external organisation community investment programmes collaborate findings ngos multilateral agencies governments community overall participants rated gsks cr performance groups information available stakeholder highly interaction following sections access medicines animal research employees suppliers government significant number also wanted understand external affairs approach corporate responsibility integrated business strategy management established panel external stakeholders addition identified six priority issues gsk provide ongoing advice comment ehs performance panel facilitated environment access medicines council independent ngo see ehs management marketing ethics advertising also seek stakeholder feedback inform research development new drugs approach managing reporting cr issues clinical trial ethics publication trial results included drug pricing engagement socially responsible investors sri meetings sri environmental impacts analysts discussed issues including access access medicines received positive feedback medicines animal rights supply chain sales access medicine programmes developing marketing ethics clinical trials fifteen sri analysts countries including preferential pricing research attended annual corporate responsibility cr diseases developing world several stakeholders briefing met senior gsk managers wanted gsk adopt tiered pricing system middle survey corporate responsibility opinion leaders income countries extend access programmes europe uk us participants included developed countries academics cr organisations customers government marketing ethics advertising respondents agencies investors media multilateral agencies felt reporting weakest marketing ethics ngos participants wanted us open survey gsk employees assessed employee marketing practices show ethical dilemmas awareness cr issues sought views addressed key cr issues gsk research praise clinical trial register section contains summary feedback information wanted research ethics received channels details relationships medical profession responding research areas chosen drug pricing participants particularly us wanted know prices set criticism profits made pharmaceutical companies gsk corporate responsibility report managing corporate responsibility continued environment participants welcomed breadth increased transparency felt show programmes quantitative targets wanted cr issues gsk considers important business environment strategy materials efficiency convey approach cr supports overall programmes gsk set ambitious co business strategy target implement programmes address majority thought gsks reporting would improved pharmaceuticals environment providing detail stakeholder engagement cr reporting influences approach cr bringing external participants asked comment cr voices report open challenges report liked comprehensive coverage increasing number performance indicators feedback investors gsk received following ratings investors rating agencies organisation rating association british insurers gsk given full rating disclosure board responsibilities policies relating social ethical environmental issues highest possible rating dow jones sustainability index gsk included djsi world index came nd sector score ftsegood index gsk included ftsegood index eiris gsk rated good eiris draft report access medicines one company achieved top rating global sustainable gsk included global sustainable companies based companies corporate knights research innovest strategic value advisors gsk one three pharmaceutical companies listed morley fund management gsks rating improved due greater disclosure management key impact areas rd developing world diseases access medicines ethical issues rd human rights ehs business ethics oekom research gsk rated best sector oekoms corporate responsibility rating received b rating improvement b sarasin bank gsk rated one three best performers industry based analysis company cr reports covalence gsk ranked top company across sectors covalences ethical ranking worlds biggest companies gsk corporate responsibility report managing corporate responsibility continued feedback employees gsks approach authorship research articles online cr survey sent randomly medical journals response concerns selected gsk employees assess awareness cr ghostwriting performance reporting total took part mainly relationship patient advocacy groups uk us response rate findings publishing list patient groups received showed financial support gsk heard term corporate responsibility approach preferential pricing middle income corporate social responsibility countries operate tiered pricing aware gsk produces corporate system responsibility report heard information pilot project assess report mygsk global news site gskcom benefits extending preferential pricing respondents felt cr issues importance products gsk ethical business conduct access information manage human rights medicines health safety standards supply chain environment information environment strategy aware gsks ethics programmes efforts improve materials efficiency access medicines health safety sometimes receive feedback suggestions rd processes employment practices stakeholders disagree unable sales marketing practices community accommodate without damaging interests partnerships environment company shareholders possible explain looking ways increase employee awareness reasons example need use animals approach cr cr reporting internal research communications programme undertaken possible provide quantitative data conduct followup survey measure meaningful indicators areas cr performance impact continue review performance indicators responding publish build possible reviewed corporate responsibility report continue engage stakeholders light stakeholder feedback addressed many understand views approach cr points made includes providing better explanation corporate responsibility cr relates business strategy discussion government external affairs challenges dilemmas encountered pharmaceutical industry highly regulated additional content provided year regulations significant impact business following areas therefore important engage debate legislation seek influence policy decisions approach public policy political lobbying affect gsk fact major multinational corporation publishing positions key policy issues often approached governments give well membership trade associations views along stakeholders ngos political donations size global reach give us access governments marketing ethics policies policy makers recognise need use implement including data number access responsibly benefit patients business employees disciplined dismissed unethical public policy work governed external affairs conduct code conduct backed factual research approach advertising consumers analysis gsks external affairs teams monitor changes approach payments healthcare practitioners proposed reforms legislation meet regularly conducting gsk clinical trials government officials explain views range public policy issues gsk corporate responsibility report managing corporate responsibility continued lobbying issues affecting whole pharmaceutical organization international investment ofii industry sometimes conducted trade pharmaceutical research manufacturers america associations may also hire professional lobbyists phrma support public policy work us lobbying expenditures gsk believes legally culturally appropriate gsk spent federal lobbying activities political donations legitimate way supporting us information reported us political process political donations policy congress accordance lobbying disclosure act governs activity area information donations figure includes salaries cost benefits given report annual report employees registered lobby us government accounts well cost hiring outside lobbying consultants addition policies governing interactions cost associated support lobbying contacts important stakeholders patient planning activities research background advocacy groups necessary addition figure includes cost running gsk washington dc government affairs section describes office support staff portion trade association fees membership trade organisations associated federal lobbying costs activities dealing us federal government us lobbying expenditure collect data lobbying expenditure political donations separately expenses countries position key issues political donations approach patient advocacy patient gsk makes political donations corporate funds groups supported donations authorized law gsk one eight companies given systematic culturally appropriate contributed rating sustainability wwf survey political organisations us canada leading companies report lobbying practices majority donations made us donations highest rating awarded company received covered gsk policy political donations systematic rating coverage lobbying indicates systems exist actively manage disclose gsk make donations political parties lobbying public policy activities company likely political organisations european union see discusses policy positions several material issues annual report information depth however approach lobbying still contributions united states fully integrated company values business principles us candidates financed primarily core business decisionmaking contributions companies individuals ngos background information approach public parties rules concerning contributions policy available external affairs section complex information exact process gskcom please go link appropriate legislation however important note corporate funds used membership trade associations support candidates federal office gsk member trade organisations including gsk corporate funds given candidates state association british pharmaceutical industry abpi level states contributions allowed biotechnology industry organization bio state law contributions accepted important way companies engage political european federation pharmaceutical industries efpia debate donated approximately intellectual property owners association ipo candidates stateheld offices us japan pharmaceutical association gsk contributions made basis political lif swedish association pharmaceutical party gsk supports candidates seek environment industry appropriately rewards highrisk highinvestment industries believes free market principles gsk corporate responsibility report managing corporate responsibility continued intellectual property rights states make information issues covered website change political donations publicly available new issues updated statements prepared current position statements found corporate contributions national political parties wwwgskcom current issues covered include candidates running federal office prohibited us law accordance federal election campaign clinical trials developing countries act gsk political action committee pac counterfeit medicines facilitates voluntary political contributions eligible employees pac controlled gsk developing world challenges access medicines participating employees legal right importation medicines set pac make contributions candidates intellectual property trips agreement political parties federal state levels gsk pac run employees contributions product diversion voluntary pac contributions subject strict preparations flu pandemic limitations example gsk pac may patient advocacy contribute excess candidate federal office per election patient advocacy groups provide members support information live pac contributions determined governing board condition represent patient views advocate pacparticipating gsk employees across issues affecting patients ' interests important company required law pac contributions stakeholder gsk engage part reported federal elections commission fec aim patientfocused company agency oversees federal election activities first half twoyear federal election cycle gsk committed ensuring company works gsk employees pac contributed total ethically patient groups groups ' candidates state federal offices independence credibility compromised global set principles supports focus contributions canada gsk donated cad approximately gsk principles working patient groups canada political candidates independence patient associations provinces legal political judgement activities shall assured contributions countries contributions made countries cooperative matters transparency vital joint policies undertaken patients position key issues associations glaxosmithkline shall based mutual respect trust wide range issues affect industry important clear positions contribute glaxosmithkline shall refrain using undue debate influence promote specific medicines services criticism companies transparent working patient associations positions key issues gsk considers glaxosmithkline always comply local definition lobby issue becomes lawsgovernance public prepare position statements assuming throughout company focused case publish position communicating principles externally patient statements many key issues website would groups well within internal training programmes impractical inefficient every issue ensure gsk employees act appropriately view however happy patient groups discuss position issue legitimate parties gsk corporate responsibility report managing corporate responsibility continued patient advocacy leaders ' summits pals one ways engage patient groups regional summits across north america individual european countries first time paneuropean summit brussels meetings give patient groups opportunity learn gsk tell company better support work typically range workshops attendees including sessions mediatraining sharing best practice patient group representatives also able discuss debate key issues relating patient advocacy healthcare policy attendees represented wide range patient groups including dedicated cancer diabetes hivaids respiratory diseases mental health epilepsy gsk european patient group advisory board formed considers voice patients strengthened across europe also sounding board allows gsk forum consult patient groups future policy direction company well forum groups raise policy issues important board independent chair european cervical cancer association made representatives series european groups usa europe gsk playing leading role within pharmaceutical industry amongst healthcare stakeholders ensure patient groups maintain independence uk gsk 's advocacy work governed association british pharmaceutical industry abpi code practice revised new code states must written agreement patient groups companies work must list patient groups receiving financial support companies gsk list available website access medicines introduction access medicine developing world research development preferential pricing voluntary licencing investment public health initiatives developed world research ethical conduct employment practices human rights environment community investment data summary gsk corporate responsibility report access medicines millions poor people developed developing countries obtain medicines need part broader problem access healthcare remains significant challenge many parts world primary responsibility addressing problem rests governments stakeholders including pharmaceutical industry important contributions make section describes gsk supporting efforts developing world improve access covers healthcare crisis many parts developing contribution developing world research world millions people access adequate preferential pricing partnerships voluntary licences food clean water sometimes political community investment important public health lacking even evident governments often initiatives resources fund clinics staff needed deliver even basic healthcare aids pricing arrangements discount cards middle pandemic made problems worse creating income countries generation orphans depriving communities patient assistance programs discount cards help greatest asset fit healthy productive people uninsured patients us tackling crisis complex challenge poverty believe response right thing fundamental cause huge barrier progress makes good business sense companies adapt significant political extra funding needed business practices address challenges new national international sources aid leaders future competitive market development build healthcare infrastructure talented people also helps us attract retain welcome additional resources promised g best people overall need make adequate returns believe responsibility governments business activities enable us invest rd intergovernmental agencies supplemented work bring new medicines vaccines patients many ngos deliver healthcare needed innovation underpins sustainability countries however pharmaceutical industry play company significant role supporting efforts finding innovative ways help poor people make important contribution developed developing countries access medicines research development diseases addressing ethical reputational commercial disproportionately affecting developing countries imperatives reasons access medicines believe gsk currently company researching strategic business driver gsk new vaccines treatments hivaids tb also support underserved communities worldwide malaria world health organizations three priority donations funding practical support see diseases much research conducted community investment public private partnerships preferential pricing specially reduced prices antiretrovirals arvs antimalarials vaccines shipped combined total million preferentiallypriced combivirand epivirtablets treatment hivaids developing world granting voluntary licences gsk granted seven voluntary licences manufacture supply generic versions leading arvs treating hivaids africa gsk corporate responsibility report access medicines continued community investment public health initiatives gsk created dedicated group pharmaceutical partnerships foster effective healthcare including rd organisation focus diseases developing major programmes tackle lymphatic filariasis malaria world ddw includes dedicated drug discovery hivaids diarrhoeal disease centre tres cantos rd site spain clinical development experts uk us ddw projects research development prioritised according social public health research development rd new drugs benefits rather commercial returns similar vaccines essential element improving health group exists vaccines organisation based belgium developing world still effective treatments widespread lifethreatening diseases many unlike many diseases disproportionately affect existing treatments diseases malaria developing world hivaids different affects becoming less effective due drug resistance developed developing countries commercial market new treatments encourages many diseases disproportionately affect developing investment required rd gsk industry leader world lack resources means often viable research hivaids treatment commercial market new treatments public private partnerships ppps helping address problem total gsk clinical programmes medicines vaccines eight diseases particularly relevant gsk collaborates several ppps including developing world seven projects diseases medicines malaria venture mmv global alliance disproportionately affect developing countries tb drug development gatb aeras global tb vaccine foundation aeras malaria vaccine initiative mvi international aids vaccine initiative iavi public private partnerships gsk wants continue investing research tackle venture mmv malaria vaccine initiative mvi diseases blight developing world however importantly new treatments resulting dilemma pharmaceutical companies must research efforts made accessible developing profitable sustain business continue world affordable price develop new medicines business model initial drug discovery diseases developing work cases prospect world ddw takes place dedicated ddw commercial return unfortunately lack discovery centre tres cantos gsk provides resources endemic countries limited profit facilities meets costs running site made new treatments many diseases scientists employed gsk tres cantos disproportionately affect developing countries half subsidised partner organisations public private partnership ppp model medicines malaria venture mmv business public sector work together offers global alliance tb drug development gatb solution problem research programmes overseen joint steering committees representatives gsk ppp companies gsk provide rd partner organisations technology manufacturing distribution expertise academic institutions may also involved providing compounds move clinical development gsk research disease area knowledge public sector provides clinical regulatory manufacturing partners governments organisations expertise resources global rd gates foundation help fund development supply network partner organisations help fund cost delivery costs ensure medicines get running clinical trials address issues access people need funds usually channelled distribution reduces costs development organisations medicines malaria gets new products patients faster gsk corporate responsibility report access medicines continued development pipeline end diseases relevant developing world focus preclinical activity phase phase ii phase iii marketed hiv protease retrovir epivir combivir ziagen inhibitor trizivir agenerase epzicom brecanavir kivexa lexivatelzir vaccines hiv streptorixs rotarix rotavirus tb malaria pneumoniae havrix hepatitis hepatitis e paediatric engerixb hepatitis b dengue fever cervarix twinrix hep ab cervical infanrixtritanrix dtp family cancer diptheria tetanus pertussis n meningitis boostrix diptheria tetanus combinations pertussis acellular polio sabin polio priorix measles mumps rubella typherix typhoid hepatyrix typhoid hepatitis varilrix varicella hiberix haemophilus influenzae type b mencevax acw meningitis malaria ntert butyl tafenoquine lapdap halfan malarone isoquine cda gsk chlorproguanil dapsone artesunate tb sitamaquine zenteldeworming agent visceral pentostamvisceral leishmaniasis leishmaniasis banocidelymphatic filariasis gsk india detailed information product pipeline found annual report isoquine enter phase progress malaria phase iib clinical trials malaria vaccine working medicines malaria venture children development years mmv world health organisation showed unprecedented results new data academic partners develop cda affordable fixed published leading medical journal lancet dose artemisinin combination treatment malaria showed vaccine remained efficacious africa based gsks existing antimalarial lapdap months several years clinical investigation november announced clinical results indicating needed vaccine ready use cda likely effective drug resistant results indicate potential help save millions p falciparummalaria found africa cda childrens lives support activity october bill progressed phase lll trials dr chris hentschel ceo melinda gates foundation announced grant mmv commented results suggest cda path malaria vaccine initiative mvi extend public could become major weapon fight drug private partnership mvi gsk biologicals resistant malaria moving phase iii trials marks key new grant directly support clinical trials step development promising antimalarial africa funds gsk least match million receives mvi help defray clinical development costs gsk corporate responsibility report access medicines continued gsk university california san gsk biologicals also inhouse aids vaccine francisco received mmvs project year award development project using companys proprietary falcipain project investigating new class compounds adjuvant technology successful aids vaccine might use malaria conducting need combine several approaches research identify candidate compounds development mixed results antiretrovirals research gsk also received project year award december announced positive results pyridones project first time study evaluating safety tolerability antiviral company successive years activity investigational protease inhibitor brecanavir following extensive development work hope brecanavir expected enter phase iii development identify suitable candidate pyridones project approved may useful treating patients first half commence phase trials infected strains hiv become resistant humans multiple protease inhibitors significant chemical pharmaceutical development october terminated clinical trial aplaviroc undertaken candidate gsk ntert ccr antagonist due concerns liver toxicity butyl isoquine malaria plan start clinical reviewing safety data followingup patients studies humans progressed red tablet versions hivaids medicines clinical development programme tafenoquine combivirand epivir developed avoid diversion became new antimalarial developed partnership first medicines kind granted positive us government 's walter reed army institute research scientific opinion european medicines agency additionally number targets emea committee medicinal products human use potential potency malaria working opinion granted article eu tres cantos site collaborators regulation allows emea give scientific opinion medicines intended use outside hivaids eu emea grant certificate november gsk institut pasteur pharmaceutical product facilitate registration announced new european collaboration develop arvs developing countries aids vaccine fusing genes human immunodeficiency virus hiv onto existing measles liquid formulations hiv medicines currently vaccine gsk license measles vaccine vector way treat young children however technology institut pasteur two entities always easy use developing world setting jointly develop aids vaccine project unicef stated access solid supported million million grant formulations would facilitate treatment older european union include development children currently assessing development production process experimental vaccine well arv tablets score line easily two clinical studies first study evaluate safety broken smaller doses help physicians profile vaccine candidate second examine carers administer right dose efficiently safely safety whether vaccine produces immune children organised hosted meeting response hiv volunteers preexisting september representatives emea immunity measles clinical studies begin fda mdecins sans frontires unicef third year five year collaboration discuss development scored tablets children partners showed great interest project earlier also launched public private understood challenges behind development partnership international aids vaccine initiative consolidating available information iavi develop aids vaccine using nonhuman document discussion regulators primate adenovirus vector technology collaboration first half firstever aids vaccine research iavi major vaccine company facilitate research gsk entered material transfer agreement vaccines types hiv circulate predominantly international partnership microbicides ipm africa agreement iavi contribute gsk select provide proprietary antihiv technical expertise funding gsk iavi compounds tested possible use microbicides researchers form joint research team prevent transmission hiv gsk corporate responsibility report access medicines continued supporting clinical trials sponsored external rotavirus organisations uks medical vaccine rotarix prevention rotavirus research council us national institutes health induced gastroenteritis launched mexico january nih hivcollaborative research programme approved countries latin resourcepoor settings twentyfour trials including america early four countries brazil panama africa currently underway mainly focusing venezuela el salvador decided vaccinate public health issues patients currently form newborn babies distributed million doses form part hiv collaborative studies latin america enough babies developing world rotavirus infection leading cause severe diarrhoea tuberculosis tb vomiting gastroenteritis children two tb kills million people year leading cause kills around children year one child every death amongst people aids developing world minute mostly developing countries rotarixwas new drugs tb discovered tested largest phase iii clinical trial ever performed years vaccine involving children since first launch rotarixhas licensed several additional gsk announced joint drug discovery countries worldwide continue seek regulatory partnership global alliance tb drug approval vaccine developing countries development gatb leading public private partnership working tb treatments gatb aims cervical cancer accelerate discovery development affordable clinical trials data presented interscience drugs shorten treatment effective conference antimicrobial agents chemotherapy multidrugresistant strains tb compounds icaac candidate cervical cancer vaccine cervarix screened ensure taken hiv showed encouraging results cervical cancer treatments since people living aids often common cause cancer deaths women susceptible tb infection gatb support fulltime developing world current published data suggest scientists working exclusively tb drug programme vaccine could reduce woman 's lifetime tres cantos gsk contribute matching number risk developing cervical cancer plan apply staff remaining overhead costs registration vaccine us europe well partnership gsk screening number compounds international region possible use new classes drugs potency leishmaniasis tb medicines discovered made affordable continued intensive development accessible possible need sitamaquine new oral treatment visceral gsk continues provide funds faculty health leishmaniasis disease affects half million people sciences stellenbosch university south africa tb year developing world usually fatal research projects projects aim identify markers untreated gsk providing funding project predict whether patients respond quickly new treatment visceral leishmaniasis urgently treatment tb likely recur needed since current medicines either impractical becoming ineffective due drug resistance sitamaquine october gsk aeras global tb vaccine shown good efficacy pilot phase ii trials foundation announced new publicprivate partnership phase iib study start investigate shorter develop gsk 's tb candidate vaccine shown treatment course positive results enable phase iii promising results earlystage clinical trials gsk studies aeras plan conduct additional trials europe involving adults previously infected tb vaccinated bacillus calmettegurin bcg studies begin africa locations test safety efficacy hivaids malaria leishmaniasis dengue fever hepatitis e vaccine candidate populations highly affected tb n meningitis cervical cancer pneumonia gsk corporate responsibility report access medicines continued preferential pricing gsk vaccines also available preferential prices work multinational organisations unicef poverty lack political insufficient medical world health organization pan american infrastructure hospitals clinics health workers health organisation governments nongovernmental biggest barriers accessing healthcare developing organisations provide appropriate affordable countries vaccines developing world includes basic affordability medicines also important polio vaccines well specially developed combination two elements first ability governments vaccines target several diseases patients pay medicines solving problem billion vaccines shipped around went require governments intergovernmental agencies developing world make significant additional financial resources available progress second element price medicines shipped million preferentiallypriced sold area gsk help address making combivirtablets majority going key medicines available developing countries africa increase last year affordable prices major commitment previous two years combined shipments call preferential pricing includes notforprofit epivirgrew tablets number prices worlds poorest countries discounted arrangements place supply prices wealthier developing countries factors preferentially priced arvs change significantly supply chain taxes tariffs distributor year markups also significant impact price medicines factors control overall shipments relatively low considering scale addressed governments hivaids epidemic growth encouraging doctors hospitals clinics needed treat hivaids malaria treatments available patients ensure better uptake preferentially notforprofit prices public sector customers priced medicines notforprofit organisations least developed countries subsaharan africa well countries eligible global fund pepfar projects means notforprofit prices offered countries notforprofit prices sustainable make profit cover manufacturing distribution costs therefore continue supply longterm notforprofit prices comparable generics combivir leading arv available day including delivery costs latest june pricing report mdecins sans frontiresshows average cost generic equivalents day lowest priced generic equivalent costs day generic prices include shipping costs insurance included prices negotiate public sector prices middleincome developing countries casebycase basis see httpwwwaccessmedmsforgprodpublicationsaspscntid contenttypepara gsk corporate responsibility report access medicines continued shipments preferentially priced combivir epivir excluding diverted stock shipments preferentially priced combivir epivir excluding diverted stock millions tablets shipments combivir epivir total stelbat fo snoillim gsk corporate responsibility report access medicines continued difficult estimate number patients treated eligibility notforprofit prices result preferential pricing agreements since gsk control healthcare provision report notforprofit prices targeted countries unled accelerating access initiative aai suggests need greatest available resources september people living lacking least developed hivaids developing countries receiving treatment countries ldcs subsaharan africa ssa least one antiretroviral supplied seven total countries addition private pharmaceutical companies aai compared employers subsaharan africa provide care people treatment includes treatment uninsured staff purchase patients africa much remains done arvs notforprofit prices notforprofit prices growth encouraging also offered country coordinating middle income countries mechanism ccm projectsfully funded global afford supply products low prices fund projects funded us presidents worlds poorest countries still make adequate emergency plan aids relief pepfar return wealthier markets nevertheless focus countries total notforprofit prices recognise many middleincome countries also need therefore offered countries assistance target countries also seek notforprofit negotiate preferential pricing arrangements arrangements facilitate access core public middleincome countries casebycase basis employees teachers nurses police fire believe best approach since disease burden fighters covered private health resources available address vary significantly insurance schemes country country arrangements combine viable negotiate prices private health sector sustainable commercial return gsk increased casebycase basis depend revenues affordability healthcare systems concerned sales private market maintain local presence several developed countries also muchneeded infrastructure developing introducing discount cards senior citizens see countries without local capacity would developed world unable provide essential services training healthcare workers use products product antidiversion measures support safety monitoring registration launch product diversion notforprofit medicines new products illegally shipped back sale wealthier countries undermines ability provide notforprofit prices list products covered notforprofit prices denies treatment intended patients poorer eligible countries available website countries introduced different packaging tablet colours many notforprofit medicines help prevent product diversion special trilingual access expected found pricing one packs approved combivir epivirand trizivir number factors affect accessibility countries received regulatory medicines lack healthcare capacity infrastructure approval red epivirand combivirtablets fundamental barriers however making countries gsk nine arvs registered products available affordable prices expand eus antidiversion regulation company usage also appeared preference registered products regulation products similarly priced generics evaluating extending preferential pricing findings pilots use inform set five pilot projects collaboration ngos strategic review business subsaharan africa tanzania uganda nigeria zambia malawi assess impact extending preferential pricing wider range products antibiotics asthma treatments vast majority global fund projects country coordinating mechanism ccm projects gsk corporate responsibility report access medicines continued voluntary licensing investment public health initiatives want play active role addressing healthcare gsk supports public community health initiatives crisis developing countries believe preferential developing countries donations preventative pricing arrangements best way medicines financial practical support able ensure delivery safe quality product focus charitable support efforts tackle affordable price long needed three major diseases lymphatic filariasis lf focus efforts situations voluntary elephantiasis hivaids malaria well licences may also help increase supply medicines phase education programme reduce diarrhoearelated voluntary licences vl enable local manufacturers disease partner nonprofit organisations produce sell generic versions products progress efforts november signed licencing agreement information community investment universal corporation kenya total programmes see community investment signed seven licencing agreements antiretrovirals arvs africa hivaids devastating progress impact includes two vls kenya five eliminating lymphatic filariasis lf south africa first granted aspen gsk founding partner global alliance pharmacare october cover parts eliminate lf wwwfilariasisorg lf disfiguring disease africa others subsaharan africa prevalent tropical countries one worlds leading causes permanent disability decision grant vl depends number factors including severity hivaids epidemic global alliance partnership country local healthcare provision economic pharmaceutical companies world health manufacturing environment vls universal organization ministries health ngos community solution hivaids specific response particular organisations aiming totally eliminate lf set circumstances committed provide many doses discuss vls potential partners casebycase albendazole antiparasitic drug used prevent basis selecting appropriate licensee key transmission lf needed treat one billion need sure manufacturer able people risk countries opened new provide longterm supply goodquality medicines albendazole manufacturing facility cape town south implement safeguards prevent diversion africa give us capability support lf medicines wealthier markets elimination efforts atrisk countries voluntary licence holders combine active ingredients donated million albendazole treatments licensed us licensed active worth million million valued wholesale ingredients produce fixed dose combinations prices countries two new countries joined also use us food drug administrations fast track programme donated million approval process arvs accelerate availability treatments since reaching million people generic arvs pepfar us presidents emergency plan also gave almost million million grants aids relief program programmes africa support global alliance eliminate lf much discussion use team gsk employees helps global alliance compulsory licences intellectual property advocacy research community mobilisation education rights taken away rights holders compulsory initiatives licenses one flexibilities world trade december gsks programme eliminate lf organisations trips agreement intellectual property top honour corporate social responsibility used humanitarian purposes gsk inaugural annual scrip awards recognise believes widespread use compulsory licences performance excellence global pharmaceutical undermine intellectual property framework biotech industries counterproductive long term rd new treatments especially commercial markets exist hivaids depends protection intellectual property gsk corporate responsibility report access medicines continued positive action hivaids gsks african malaria partnership recognise need support communities african malaria partnership supports education affected hivaids longstanding commitment behaviour change programmes eight african countries part community investment set partnerships freedom hunger amref positive action aims strengthen capacity plan international community based organisations providing hivaids gsk invested million african malaria healthcare services increase number people partnership three years expected benefit coming forward testing treatment reducing two million people encouraging effective stigma discrimination recognises involving people prevention prompt treatment particularly among affected hivaids key controlling hiv pandemic children pregnant women launched new positive action programmes india gave million three kenya mexico year grant new partner malaria consortium uk positive action programmes running countries ngo launch mobilising malaria initiative aims positive action supporting reach india project focus attention malaria generate political aims make hivaids prevention financial business commitment sustained funding combat education available millions poor women rural disease generate media coverage increase india gsk giving used number ngos community organisations engaged develop capacity community organisations tackling malaria give african communities selfhelp groups reach women rural areas first knowledge tools need prevent three years expected benefit women transmission malaria million family members reach india project personal hygiene sanitation education phase freedom hunger supported catholic relief every year two million people die diarrhoea services positive action related disease mostly children developing countries kenya gsk giving million million three deaths often easily prevented better years integrate hivaids treatment support services hand washing sanitation general healthcare clinicsthis enable phase helping reduce diarrhoearelated disease patients avoid stigma visiting hiv clinic fewer encouraging school children wash hands gsk kenyans know hiv status fear established phase invested million stigmatisation significant barrier people seeking million programme phase run testing diagnosis treatment services positive action partnership amref plan international well also focus training healthcare professionals ministries health education creation patient selfhelp groups increase awareness support patients sticking programme impressive results example treatment regimes programme collaboration study amref kenya showed four years gsk amref african medical research children participating schools washed foundation elizabeth glaser pediatric aids foundation hands using toilet compared national empowerment network people living nonparticipating schools hiv aids kenya phase extended bangladesh mexico launched threeyear project operates six countries bangladesh first asian international hivaids alliance mexican partner country take part phase first year colectivo sol project aims improve quality programme implemented schools reaching life people hivaids reduce stigma children gsk working new partner discrimination help people protect bangladesh save children usa phase hivaids education awareness raising integrated save childrens existing school health nutrition programme ensure projects long information arrangements supply hivaids term sustainability gsk funding finishes medicines preferential prices developing countries see preferential pricing gsk convened phase steering committee representatives partner organisations help source kenya demographic health survey expand programme countries httpwwwmeasuredhscomhivdata gsk corporate responsibility report access medicines continued developed world january gsk nine pharmaceutical companies created new card improve access access medicines issue developing medicines uninsured americans seniors world even developed countries patients together rx accesscard provides savings afford medicines need particular medicines approximately million problem us many people people around uninsured people us health insurance gsk developed patient assistance eligible enrol participating companies enrolled programs discount cards us help patients people received without insurance prescriptions worth million based wac also introducing discount cards several middle gsk assisted patients income countries enable qualifying patients obtain prescriptions worth million prescription medicines discount price orange cards middle income countries programmes us gsk introduced orange cardsproviding discounts patient assistance programs provide prescription medicines certain gsk prescription medicines eligible patients lowincome uninsured patients free minimal cost bulgaria lithuania ukraine nature gsk operates several programmes including commitment discounts varies countries depending accesswhich covers cancer treatments bridges needs patient way healthcare accesswhich covers medicines outpatients system operates patients registered one phone call orange cardin ukraine gives asthma patient advocate receive medicine local chronic obstructive pulmonary disease patients pharmacy mail order patients average discount received gsk medicines worth million gsks seretide asthma medicine asthma patients programmes compared million age suffer disabilities affected value medicines calculated using chernobyl nuclear disaster also eligible eligibility wholesale acquisition cost wac assessed patients doctor patients receive gsk first pharmaceutical company us medicine participating pharmacies hotline offer card providing savings medicines lowincome number set help patients find nearest senior citizens disabled people known orange pharmacy patients enrolled received cardthis enabled people buy gsk outpatient discounts worth prescription medicines discount lithuania orange cardgives senior citizens orange cardholders received average discount patient copayment prescriptions saving million based wac gsk prescription medicines far gsk six pharmaceutical companies patients applied orange cardand established together rxcard provided discounts pharmacies registered participate prescription medicines lowincome senior patients received discounts worth citizens eligible medicare december widened group eligible people received gsk prescriptions orange cardto include disabled people programme saving million based wac gsk orange cardwas also introduced bulgaria access programmes us change significantly may lowincome patients chronic diseases launch new medicare prescription asthma chronic obstructive pulmonary disease drug coverage programme orange cardand diabetes card holders receive average together rxprogrammes finished december discount four gsk prescription medicines patients eligible new medicare patients received discounts worth euro programme report rollout million million changes next year gsk corporate responsibility report access medicines continued summary gsk discount programmes country gsk programme number patients value benefit patients us patient assistance programs free received million minimal cost medicines lowincome prescriptions uninsured patients us orange card discounts lowincome received million senior citizens disabled people prescriptions us together rx discounts lowincome received million senior citizens joint industry programme prescriptions us together rx access discounts received million lowincome uninsured patients joint prescriptions industry programme bulgaria orange card discounts lowincome patients million patients chronic diseases received prescriptions lithuania orange card discounts senior citizens enrolled disabled people ukraine orange card discounts asthma enrolled medicine patients case study prescription combating global diseases medicines malaria venture mmv manages largest portfolio malaria drug research malaria kills one million people year mostly history projects different stages children developing countries beyond human development gsk one several partners mmv toll malaria costs africa least billion year along academic institutions biotech firms lost growth accounts around public pharmaceutical companies health spending one mmv projects cda affordable fixed recently little research devoted dose combination treatment malaria africa cda malaria developing world diseases based gsks lapdap one first new developing countries often dont money malaria treatments developed ppp pay new medicines little incentive clinical trials showed cda may effective companies develop drug resistant malaria last five years public private partnerships ppps similar partnership malaria vaccine initiative transformed research landscape malaria accelerating development malaria vaccine developing world diseases gsk involved gsk clinical trials showed several partnerships ppp public sector vaccine mosquirix efficacious children aged organisations including governments private month period first time vaccine foundations bill melinda gates proved efficacious parasitic disease foundation help fund research may also help humans results demonstrate feasibility developing countries purchase new products developing efficacious vaccine malaria registered could significantly contribute reduce intolerable global burden disease research introduction access medicine research animal research conduct clinical trials training auditing clinical trials clinical trial information results ethical conduct employment practices human rights environment community investment data summary gsk corporate responsibility report research research development rd new medicines vaccines core business makes significant contribution society new medicines vaccines brought huge benefits health quality life millions people last years continued rd remains important ever still many serious debilitating life threatening illnesses effective treatments treatments could significantly improved invested billion billion animal research employed people rd goal animal research essential understand disease build best product pipeline industry evaluate safety effectiveness new medicines research aims meet unmet medical needs pipeline vaccines given people includes compounds potential make major contribution healthcare developing countries see regulations require new medicines tested access medicines although work essential animals tested humans safety reasons often little return investment new vaccines tested animals time treatments area seek partners help fund new batch produced estimate animal research projects accounts around gsk research expenditure throughout rd process seek views gsk animal research laboratories europe japan patients inform research focusing patient needs singapore us research around drives innovation brings commercial success total animal research conducted external contractors behalf percentage remained relatively recognise biomedical pharmaceutical constant last three years research raises ethical concerns use new technologies objective reporting clinical trial animals used gsk rodents results committed attaining high ethical rats mice guinea pigs rabbits remaining scientific standards rd work section includes fish ferrets pigs dogs cats primates explains approach goal use animals scientifically animal research efforts reduce refine necessary use animals possible replace animal testing minimise distress animal research laboratories subject strict internal legal controls gsk conduct clinical trials ensure gsk committed rs reduction refinement sponsored clinical trials carried replacement achieving highest standards ethical standards irrespective animal welfare run award programmes encourage conducted implementation rs share best practice others training auditing clinical trials train industry communicate approach gsk employees involved clinical trials interested parties check trials carried good clinical practice approach impact despite significant gcp standards increase rd activity since number animals clinical trial information results publicly used gsk laboratories broadly similar disclose trial information results journal eleven years ago articles gsk clinical trial register public databases background information approach new technologies available website gsk corporate responsibility report research continued animals used gsk mouse rat guinea pig rabbit rodent animals used gsk animal used mouse rat guinea pig rabbit rodent gsk corporate responsibility report research continued change rd activity compared change number animals used gsk research laboratories figures normalised levels change rd activity compared change number animals used gsk research laboratories year animals used rd acivity around total animal research conducted external contractors behalf percentage remained relatively constant last three years ecnis egnahc rd activity animals used gsk corporate responsibility report research continued three rs sharing best practice rs commit us reducing number animals gsk participated study uk associate used study refining studies minimise pain parliamentary group animal welfare use maximise information obtained animal animals vaccine testing humans information replacing animal studies alternative methods work develop new tests vaccines wherever possible replacement primates mice testing oral polio vaccines included final report published recent gsk advances research techniques supporting march see rs animal welfare httpwwwapgaworguserimagesvaccinetestingpdf redesigning animal studies refining testing annual gsk laboratory animal welfare prize methods outputs eg biomarkers similar recognises external researchers laboratories developing measured blood tests human clinical trials best new techniques implementing rs obtained animal alive increase prize reduces total number animals needed awarded new uk national centre rs obtain data together industry partners association use radiotelemetry technology enables british pharmaceutical industry funding new continuous measurements made eg blood threeyear post national centre rs pressure heart rate temperature without encourage sharing industry best practice disturbing restraining animal regulation internal controls observation nighttime activity marmoset laboratories comply strict national laws monkeys resulted improvements nest guidelines codes conduct animal welfare boxes resting sleeping regulators carry regular unannounced inspections see website background information sites check standards animal care implementation rs gsk ensure appropriate use animals proposed animal training awareness tests must reviewed ethical review committee provide extensive training rs staff gsk laboratories external laboratories conducting involved care use animals research behalf must follow code practice number initiatives increase awareness animal animal research includes best practice standards welfare example produce quarterly bulletins animal care use reviewed updated review recently published journal news items code practice policies subjects ukbased rs committee made 'best practice ' defined combination gsk scientists statisticians senior managers animal currently known scientific literature technicians veterinarians encourages rs culture published recommendations knowledge gsk seminars production promotion experts within outside gsk independent recommended practice guidelines scientific accreditation association accreditation procedures animal welfare assessment laboratory animal care aaalac animal welfare awards encourage employees find international one way laboratories demonstrate alternatives animal research awards presented meet best practice gsks rd chairman recognise employees ten laboratories accredited aaalac made outstanding advances implementing rs including animal laboratories belgium italy awards made development spain uk us present vast majority use advanced medical imaging systems minimise animals used gsk aaalac accredited facilities animal use aim achieve aaalac accreditation gsk animal technician awarded andrew laboratories conducting animal research blake tribute award seriously ill medical research communicating approach uk national patients group support humane animal testing clearly sensitive issue animal research paper improvements people hold strong views believe important housing husbandry welfare ferrets gsk gsk corporate responsibility report research continued explain need animal research open clinical trials wherever carried conducted according good clinical practice gcp guidelines developed international conference gsk took part twoyear detailed ethical review harmonisation ich principles contained nuffield council bioethics ethics research world medical association declaration helsinki involving animals published concluded ethical principles medical research involving human animals useful models studying specific aspects subjects ich guidelines provide human biology disease likely effects internationally accepted ethical scientific quality chemicals medicines humans however standard designing conducting recording usefulness animal models judged reporting trials cover issues selection casebycase basis type research testing training trial investigators gaining informed consent report recommended information made trial participants monitoring quality assurance available goals welfare implications animal policies ensure medical practitioners research alternative scientific methods enable running gsksponsored clinical trials selected interested parties judge whether specific types recompensed appropriately policy payments research justifiable emphasised importance healthcare practitioners institutions conducting gsk using alternatives animal research development sponsored gsksupported clinical studies states new alternative methods condemned use clinical trial investigators must selected solely violence intimidation opposed animal qualifications conduct clinical research history research gsk endorses reports findings using gsk products must taken account laboratories host visits schools colleges animal payments practitioners reflect fair market value welfare organisations others also made work performed payments offered made visits uk schools visits us could influence judgement whether enrol schools community groups discuss issues around maintain participant clinical study animal research engage regularly animal welfare standards clinical trials organisations investors interested parties trial protocols plan clinical trial well contributing debate media conducted reviewed external regulatory agencies article animal research impact relevant countries required protocols animal rights extremism financial times noted considered relevant ethical review committees whose glaxosmithkline led uk pharmaceutical industry remits cover sites studies take place cautious move towards openness use ethics review committee composed lay people animals october medical professionals scientists assess whether accept legitimate right lawfully protest trial justified whether designed animal research part free society condemn conducted according appropriate ethical standards use violence intimidation opposed ethics committees power reject stop animal use clinical trial safety data routinely collected throughout conduct clinical trials development programmes reported regulators line applicable regulations well safety effectiveness new medicines must reviewed gsk ongoing basis safety evaluated human clinical trials signals gsk global safety board responsible approved marketing regulators give approval approval pivotal protocols internal assessment trials demonstrate product safe effective issues related patient safety arise benefits outweigh risks potential development programme audit clinical trials ensure side effects conducted appropriate standards see new product typically tested three training auditing clinical trials stages clinical trials involve healthy individuals patients relevant disease projects clinical development gsk corporate responsibility report research continued clinical trials outside western europe number scale trials taking place north north america america western europe increases difficult gsk conducts clinical trials answer scientific questions find experienced investigators able start meet regulatory requirements seek conduct trials recruit suitable patients quickly fewer patients clinical trials enrolled trials countries easier find participants speeds research process population relevant scientific question helps ensure new medicines get patients quickly results generalised broader patients countries often used fewer populations medicines north america western high quality data obtained europe makes good candidates clinical costs minimised trial easier assess effect medicine tested clinical trials take place western europe north america trials developing countries also conducted regulators around world require significant evaluate new medicines many different diseases amounts clinical data approve medicine include diseases previously considered impacts pool available patients north prevalent developed world america western europe increases costs common developing countries therefore associated conducting clinical trials looking increase number patients recruit countries recruitment costs per patient countries trials central eastern europe asia south america outside north america western europe lower south africa addition gsk ongoing thereby allowing pharmaceutical companies meet commitment invest research development regulatory requirements financial demands targets diseases disproportionately affect relevant populations developing countries eg malaria clinical trials gsk committed investing rd diseases developing countries usually required develop disproportionately affecting developing countries see investigational compounds important note access medicines compounds must usually clinical trials investigational medicines tested clinical trials developing countries conducted countries known outset disease prevalent medicine relevant intent pursue registration make local population example incidence malaria medicine available use country developed world low means development medicines conduct scientifically robust clinical trials new gsk starting perform trials regions malaria treatments developing countries central eastern europe south africa latin america concerns trials regions may parts asia several reasons carried high standards healthcare infrastructure clinical trial capabilities western europe north america gsksponsored regions improved significantly recent clinical trials conducted ethical standards years example many physicians working irrespective location studies meet international developing countries trained educated national regulatory legislative requirements global standards therefore clinical trials conducted accordance principles good readily conducted effectively monitored clinical practice gcp principles contained countries world medical association declaration helsinki ethical principles medical research involving human changes living standards mean diseases previously subjects common developed world eg hypertension diabetes becoming prevalent developing leastdeveloped countries additional countries including patients many ethnic measures often needed example cultures backgrounds enables us develop medicines truly western society still complying global fashion helps us evaluate whether new ethical legal requirements additional steps taken treatments suitable different ethnic groups match objectives informed consent local culture example local leaders andor family members may need involved gsk corporate responsibility report research continued posttrial treatment keep detailed training records routinely sometimes asked happens patients requested regulatory authorities undertaking treatment end trial inspection assess competence employees undertaking clinical trials important realise gsk general responsible provision nationally licensed gsks internal audit department conducts audits gsk medicines treatments already approved use systems processes involved conduct trials trial reason gsksponsored clinical trials well auditing clinical research organisations chronic conditions carried unless investigators performing clinical research behalf assured outset national healthcare system audits conducted able provide responsible continued audits investigator sites conducting gsk care trial participants trial importantly sponsored trials represents approximately patients initiated nationally licensed medicines investigator sites participating pivotal clinical trials trial chronic disease need assured pivotal clinical trials trials provide suitable alternatives primary data regulatory approval based medicines made available trial audits internal gsk systems processes used patients derived measurable medical benefit managing clinical trialsdata gsk also recognises may circumstances audits clinical research organisations carrying compelling medical rationale patients clinical trials gsks behalf derived measurable medical benefit investigational compound medicine yet audits gsk medical departments based specific approved clinical trial continue countries receive compound example illness audits conducted response suspected treated life threatening seriously debilitating irregularities treatments available significant risks switching patients alternative audits resulted findings needed treatments case posttrial treatment investigation investigators reported investigational compound provided regulatory agencies appropriate oversight example clinical trial audit results reported quarterly rd risk setting gsk commits provide investigational management compliance board annually compound long necessary gsk audit committee concerns issues identified compound approved licensed country audits fully investigated appropriate action taken may include retraining severe cases dismissal individuals concerned well training auditing clinical trials development new training programmes procedures provide training ensure clinical trials prevent reoccurrence trial data may also performed high ethical quality standards audit analysed conduct clinical trials ensure carried according good clinical practice gcp guidelines inspections investigators clinical research organisations independent ethics committees iecsinstitutional review employees involved designing conducting boards irbs sponsors clinical trails also carried monitoring gsksponsored trials trained gcp regulatory authorities ensure safety trial training mandatory employees must participants quality data trials completed required training starting conducted according gcp changing jobs training inspections gsk investigators activities related gcp training activity represents used gsk conduct clinical studies successful completion elearning module instructorled course related gcp one employees complementary workers gsk corporate responsibility report research continued clinical trial information results gsk follows phrma principles conduct clinical trials communication clinical trial make results clinical trials widely available results committed timely communication healthcare practitioners others use evaluate results products approved marketing use medicines also publicly disclose information ongoing trials wherever possible publish trial results peer reviewed scientific medical journals conference ongoing clinical trials abstracts proceedings used research publicly available internetbased registration ongoing healthcare communities obtain latest information clinical trials provide stimulus increased treatments participation clinical research also provides important reference point interested parties track gsk guarantee publication methods since subsequent disclosure clinical trial results discretion journal editors conference organisers reason launched gsk online gsk legally required post summary protocol clinical trial register supplement prescribing information ongoing studies treatments serious information publications scientific literature lifethreatening diseases conducted us register contains results protocol information investigational new drug application national gsksponsored trials marketed medicines also institutes health website wwwclinicaltrialsgov provides references publications appeared made additional commitment post medical journals anyone use internet access protocol summaries patient clinical trials irrespective register countries involved initiated november ongoing july clinicaltrialsgov concerns ghost writing journal end protocol summaries articles doctors put names articles written actively recruiting clinical trials clinicaltrialsgov pharmaceutical companies gsks approach authorship acknowledgements articles must postings meet requirements international consistent journal guidelines must committee medical journal editors nonphase iii determined based level contribution study trials policy delay registration certain data design data acquisition analysis interpretation elements exceptional basis writing revising manuscript named competitively sensitive senior author paper must actively participate clinical trial results drafting process lead content development pharmaceutical companies legally required disclose manuscripts senior author works closely relevant data clinical trials appropriate coauthors retains final approval authority regulatory authorities seeking approval new manuscript gsk staff contractors contribute product development manuscripts external authors must named article approval sponsors continuing obligation provide regulatory authorities updated safety activity information clinical trials ensures regulators end clinical trial accurately assess safety effectiveness new summaries gsk clinical trial register medicines monitor safety safety efficacy httpctrgskcoukwelcomeasp includes information provided doctors prescribing clinical trials major marketed products information approved regulators completed since merger gsk completed merger likely inform addition need use ways medical judgement continuing populate appropriately communicate results clinical trials register clinical trials relate marketed healthcare practitioners others use evaluate medicines completed use medicines gsk corporate responsibility report research continued number publications gsk clinical trials gsk clinical trial register cumulative total number publications gsk clinical trials gsk clinical trial register cumulative total year publications snoitacilbup fo rebmun objective publish trial results new products gsk complies corporate policies procedures within months product reaching market established fulfill commitment make publish results trials completed product information clinical research activities available approved marketing within one year trial completion public addition actively involved sharing views experiences clinical trial registration independent assessment documentation processes advisory board process established procedures used gsk populating clinical world health organization establishing trial register httpctrgskcoukwelcomeasp international clinical trials registry platform conducted external organisation continue httpwwwwhointictrpen engage services organisation ensure gsk corporate responsibility report research continued case study diabetes research gsk potent compound first tested human clinical trials avandia treatment type diabetes one gsks top selling medicines avandiawas launched complex diseases type diabetes outcome research began failure rate research high despite significant years earlier investment rd pharmaceutical industry new drugs introduced years type diabetes two causes inability insulin sensitisers avandia became produce enough insulin insulin resistance available avandiahas used inability respond insulin available causes seven million people worldwide helping rise blood sugar devastating control disease improve quality life consequences patient including blindness heart attacks strokes diabetes research gsk stopped investing million several large beecham gsk legacy company began researching outcome studies assess effect avandiaon type diabetes time longterm complications diabetes see two types oral sugarlowering drugs available whether used prevent atrisk people worked stimulating body produce developing disease two new combination insulin helping liver control blood treatments avandametand avandaryl sugar levels treatments successful launched combine avandia diabetes everybody furthermore diabetes treatment treatments makes easier patients remains effective one patient forever disease maintain treatment regime gsk another progresses patients must combine number novel diabetes drugs clinical trials ongoing different drugs research programme metabolic research centre beecham focused research treatments used north carolina new mechanism combating insulin resistance rapid increase obesity major cause type area little known took six years diabetes appearance disease children research promising compound makes research important ever identified team developed novel ethical conduct introduction access medicine research ethical conduct code conduct marketing ethics marketing codes practice consumer advertising training awareness monitoring compliance employment practices human rights environment community investment data summary gsk corporate responsibility report ethical conduct gsk fully committed ensuring business practices meet high standards ethics legal compliance employees behave honesty integrity important get right way conduct business affects patients consumers use products doctors prescribe medicines governments regulate industry reputation reputation stakeholders critical business reputation also affects ability attract retain motivate best people meeting high ethical standards enables us maintain support stakeholders retain licence operate section explains approach business code conduct marketing ethics performance covers employee guide business conduct sets gsks code conduct management certification standards behaviour expect employees well business ethics key compliance ethics policies guide business activities requires employees act approach marketing ethics including integrity comply law avoid conflicts interest marketing codes practice updated policy report violations law gsks policies directtoconsumer advertising unethical behaviour training awareness programmes reinforce guidance provided including reallife examples importance ethical conduct ensure constitutes acceptable unacceptable behaviour employees understand standards behaviour gsk employees access guide via company required intranet induction training familiarises new monitoring compliance systems including role employees business conduct standards provides corporate ethics compliance department information obtain support channels receiving reports alleged cases answers questions misconduct data number employees management certification business ethics dismissed disciplined violating company policies including code conduct commitment code conduct reinforced annual management certification programme information ethical issues rd available requires managers certify comply research section report includes policies statement expanded programme governing relationship doctors involved clinical include managers worldwide eligible trials see conduct clinical trials policy managers business units worldwide disclosure clinical trial results writing articles completed certification certification documentation medical journals see clinical trial information results managed electronically noncertification tracked information relationships governments followed noncertification typically due available section government external extended leave absence maternity leave affairs policies making products longterm sick leave widely available see access medicines background information ethics policies available website gsk corporate responsibility report ethical conduct continued full certification statement reproduced three markets france germany belgium links included statement certification process slightly different accessible via internal intranet however code reflect local legal requirements conduct employee guide business conduct business ethics suppliers documents available responsibility section gsk produced booklet help suppliers wwwgskcom understand requirements must meet order work gsk booklet outlines importance gsk places operating high ethical standards certify includes reference gsk policy gsk understand gsk committed employees bound prohibits acceptance principle performance integrity gifts entertainment working gsk suppliers particular ensuring activities comply asked understand respect position applicable laws supplier gsk asked adopt follow high standards within business received copy access interactions gsk gsk code conduct polgsk gsk corporate policies corporate policy index link intranet site marketing ethics read understand employee gsk markets medicines doctors hospitals guide business conduct accessible link governments countries us intranet site japan also advertise medicines directly consumers complied applicable laws specialist sales representatives meet regularly regulations gsk corporate local doctors pharmacists inform policies procedures medicines approved uses people supervision received believe sales representatives play copies access gsk code important role providing uptodate information conduct gsk policies doctors products benefits patients informed responsibilities however recognise marketing pharmaceutical products raises challenging issues put place appropriate measures particular people concerned marketing ensure people supervision pharmaceutical companies exerts undue influence comply laws regulations gsk doctors sales representatives always give corporate local policies procedures doctors full information potential side effects working behalf gsk promotion unapproved uses may common understand responsibility promptly despite increased compliance training monitoring report actual suspected violations activity oversight governments law regulations gsk corporate local sale promotion pharmaceutical products policies procedures highly regulated governments medical agencies reported actual potential several governments extending legislation area compliance issues aware instance us proposed laws concerning legal requirements company pending state legislatures could require policies pharmaceutical companies restrict report interactions doctors exceptions list compliance issues reported previously gsk employees must also comply marketing codes practice policies governing consumer advertising codes require marketing based valid scientific evidence consistent national prescribing documentation comply law gsk corporate responsibility report ethical conduct continued updated strengthened appropriate hospitality meetings entertainment policies procedures permitted hospitality travel costs food may provided meetings educational sales marketing employees receive training ensure purpose level hospitality must appropriate good understanding marketing policies occasion must provided relevant legal framework governing sales activities healthcare professionals spouses children office also programmes monitor compliance personnel guests travel costs including regions feedback doctors provided us sales practices regional codes available local gsk rated third survey french doctors languages employees access via conducted insemma marketing research institute intranet sales marketing staff receive training assessed well pharmaceutical companies comply codes see training awareness industry marketing code copy gsk european promotion medicines doctors noticing gsk taking leadership code practice available online report stance areas gifts entertainment particular reactions vary well done gsk setting good progress example others industry follow gsks president pharmaceutical operations majority reaction wont pay spouse direct reports conducted review regional travel ill go another company marketing codes confirm gsks codes minority reaction one particular case uk comprehensive consistently applied regions recently gsk offered sponsor doctor attend identified certain areas improvement congress asked gsk pay wife update codes accordingly changes accompany congress gsk manager include reducing maximum value nominal gifts refused request contrary marketing healthcare professionals less code practice doctor sponsored another prohibiting gifts entertainment medical company attend congress professionals retained consultants gsk also ensure decisions grants medical education marketing codes practice donations charitable purposes reviewed pharmaceutical marketing promotional activity departments independent sales marketing policy applies employees agents commits us promotional practices ethical responsible launched new procedure europe sponsored principled patientcentred prohibits kickbacks attendance doctors medical conferences bribery inducements doctors procedure specifies circumstances sponsorship appropriate governs provision policy supported regional marketing practices appropriate travel meals accommodation codes europe international region japan us codes apply ethical standards compliance policies procedures formal reflect differences market structures national healthcare performance objective sales marketing employees systems regulations incorporate principles us evaluated part employee industry codes practice efpia ifpma performance reviews thus encouraging employees view jpma phrma marketing codes compliance integral part overall performance us employees pharmaceutical business codes explain policies issues appraised following objective providing full accurate information information consistently follow company policies provided approved uses medicine procedures take complete required compliance information must accurate balanced fair objective training timely manner report compliance unambiguous uptodate issues manager legal compliance gifts healthcare professionals gifts must given occasionally must relevant practice medicine gifts made inducement prescribe medicines gsk corporate responsibility report ethical conduct continued addition managers evaluated following designed educate consumers medicine objective condition prescribed dtc advertising pharmaceuticals must accurate supported ensure supervised employees trained evidence must also include information risks company policies procedures taken benefits treatments options diet required training provide oversight lifestyle changes principles available direction supervised employees wwwphrmaorg compliance company policies procedures gsk early supporter new principles consumer advertising reviewed updated marketing policies section explains approach advertising incorporate phrma guiding principles well prescription medicines us advertising additional requirements ensure compliance consumer healthcare products markets new provisions implemented updated directtoconsumer advertising dtc policy include us advertise prescription medicines elimination reminder advertisements short consumers tv print advertisements advertisements mention pharmaceutical known directtoconsumer dtc advertising dtc brand name medical condition advertising permitted markets designed treat although new zealand bangladesh korea allow submission new television ads fda review limited dtc advertising least days advance stage promoting use prescription drugs directly development audio visual components consumers controversial critics believe areavailable encourages people request unnecessary treatment providing information treatment options adding burden healthcaresystems diet lifestyle changes advertised believe responsible pharmaceutical advertising condition treatment options referenced useful source health information patients prescribing information product helps increase awareness conditions patients might requiring reference phrmas partnership appreciate otherwise know educates prescription assistance branded print ads patients treatment options patients must still branded websites programme directs patients consult physicians condition members companies low income patient assistance appropriateness prescription medicine obtain programs consent receiving medicines countries us wheredtc advertising marketing practices nonpharmaceutical common industry practice need ensure products products also promoted way advertise overthecounter medicines oral healthcareproducts nutritional products bangladesh run dtc campaign vaccines consumers worldwide advertising governed includes television commercial newspaper national regulations codes practice advertising advertisements campaign titled vaccination internal policies procedures meet exceed run period three years local laws international commercial excellence exchange award internal gsk awardand approved advertising consumer healthcare medicines local regulatory authority nutritionals generally subject less stringent directto consumer advertising requirements prescription us pharmaceutical industry association medicines gsk consumer healthcare global phrma introduced new guiding principles dtc advertising guidelines require claims advertising prescription medicines consumer healthcaremedicine advertisements launched january consistent product labelling markets allow principles state companies spend comparative advertisements gsk consumer healthcare appropriate amount time educating doctors guidelines require comparison gsk product healthcare professionals new drugs acompetitorsbe supported adequate data consumer advertising begins advertising previous version report incorrectly stated advertise prescription medicines consumers japan advertising prescription medicines consumers illegal japan advertise prescription medicines consumers japan however run dtc advertisments raise awareness disease among patients general public without mentioning prescription brands gsk corporate responsibility report ethical conduct continued uk concerns advertising food training new sales marketing employees covers drink contributing rise childhood obesity marketing codes practice induction courses uk governments health select committee ensure new employees understand importance made recommendations tackling obesity including ethical conduct day one know deal restrictions advertising children placement dilemmas seek help vending machines schools provide additional training employees gsk consumer healthcare guidelines advertising working areas additional regulatory children meet exceed local laws codes requirements rd manufacturing sales practice guidelines advertising children prohibit marketing drug advertising designed appeal targeted sales representatives receive detailed training children legally mandated minimum age medicines promote diseases example uk buy advertising space designed treat sales employees given training childrens media supply vending machines appropriate marketing practices required pass primary schools test marketing code starting sales role sports star sponsorship important brands regular refresher courses held sales lucozade sport guidelines sponsorship state marketing employees least annually example people set appropriate example markets employees look examples ethical used sponsorship appeal dilemmas issues could face work solely children age guidance provided help understand us advertising overthecounter medicines must appropriate responses employees encouraged ask comply governmental advertising guidelines following questions making advertiser must reasonable basis making claim decision publishing comparative advertising overthe would embarrassed friends family knew counter medicines permitted us long decision made claims truthful misleading consumer testimonials celebrity endorsements permitted would decision look cynic long statements made reflect honest opinion could newspaper headline look like speaker true deceptive still confident right decision gsk consumer healthcare member gsk consumer healthcare products association chpa monitor success training awareness voluntary code advertising practices programmes example us conduct surveys nonprescription medicines guidelines advise gsk sales representatives survey revealed practices advertising implies casual attitude toward using drugs suggests overthecounter drug prevent cure serious disease must employees rated efforts promote treated licensed practitioner gsk consumer compliance effective healthcare advertising reviewed ensure meets representatives correctly answered government industry standards questions promotional materials sample management policies training awareness employees suggested solutions handle compliance challenges training awareness programmes make sure employees understand policies comply also conduct global management survey every two law know standards behaviour required years survey showed managers said understood gsk code conduct training starts induction course new applied jobs employees uk us covers gsk code conduct relevant policies induction gsk corporate responsibility report ethical conduct continued activity monitoring compliance launched new half day workshop ethical recognise strong policies codes practice decision making attended almost good training guarantee employees senior managers us uk including staff meet standards internal compliance systems corporate functions finance hr designed identify address breaches codes communications workshop gave participants section covers practical tools help making ethical decisions highlighted managers obligations employee role corporate ethics compliance guide business conduct risks associated department noncompliance channels employees report concerns managers attended ethical decision suspected cases misconduct number type making workshops chose attend recognised contacts channels need involve engage managers address misconduct number employees throughout gsk ongoing basis dismissed disciplined misconduct launch additional ethics elearning facetoface training package managers corporate ethics compliance function corporate ethics compliance department works new sales marketing staff us gsk business units promote effective risk received training compliance policies management compliance programmes identify existing staff received two hours annual address compliance issues ensure appropriate refresher training track sales oversight upward reporting gsk senior marketing training hours countries anther management board dedicated initiative improve employee understanding yearly fulltime compliance officer seven major bulletin launched us pharma compliance office business units rd manufacturing biologicals pharma major types unethical conduct detected europe international pharma japan pharma us actions taken pharma addition corporate compliance officer rd employees completed performing reports directly ceo integrity course course compliance officers senior managers direct access established rd leadership teams gsk functions employees completed course includes training source expertise anyone question ethics code conduct policies conflicts compliance gsk policies compliance officers interest acceptance gifts entertainment define training needs communicate latest gsk employees developments new policies legislation affecting objectives gsk well deliver training assess compliance review performance integrity facetoface issues business units many markets also appoint induction training session make appropriate local compliance champions changes new staff uk us us appointed four compliance staff sales marketing compliance advisers role launch additional ethics elearning facetoface provide feedback infractions conduct customised training package building ethical decision training recommend process improvements making workshop managers also hired trained staff new compliance data analysis reporting group group already begun analyse monitoring investigation data highlight suitable areas focus follow business unit us gsk corporate responsibility report ethical conduct continued sales representatives supervised sales managers doctors raise concerns report unethical regularly monitor educational events visits conduct gsk sales representatives doctors expenses also independent customer response centres market research monitors review records number key risk areas via industry associations phrma abpi us internal audit department continues deploy staff retrained deal concerns marketing significant resources provide regular audits business practices might raised healthcare professionals processes including auditing sales marketing patients public redirect calls appropriate practices globally result audit findings senior management compliance officer necessary decision making process grants donations addressing misconduct updated europe international region corporate ethics compliance department decisions made relevant medical monitors tracks allegations suspected cases department instead commercial staff legal ethical policy infractions also ensures european code marketing practice includes allegations appropriately investigated disciplinary quarterly reporting mechanism markets confirm action including dismissal taken whether breaches code practice necessary occurred severity breaches actions taken prevent recurrence reports reviewed senior managers similar procedure employees disciplined misconduct monitoring expenses launched compared highlighted inconsistencies across countries dismissed agreed leave areas improvement countries company voluntarily compared european region receive central direction regarding monitoring expenses relevant disciplinary actions included verbal written expenditure warnings instances financial penalties employees staying company received reporting channels training increased monitoring employees encouraged seek help report numbers increased since believe concerns suspected cases misconduct probably due better reporting breaches people line management compliance officer become familiar reported confidential integrity helplines offsite anticipated numbers may continue post office box us increase detection reporting helplines post office box promoted mechanisms refined employee guide business conduct gsk disciplinary actions included cases intranet training corporate ethics employees breaching sales marketing codes compliance function promoted source cases resulted dismissals separations information advice well mechanism company also verbal warnings reporting concerns written warnings included many small spends allowed limits hospitality scientific meetings contacts compliance functions mainly us increase last year employees seeking advice information employees reporting suspected cases misconduct outside us mechanisms track information evolving general trends issues visible senior management addressed action necessary employment practices introduction access medicine research ethical conduct employment practices employee surveys diversity employee development talent management internal communication health safety manage health safety injury illness rates causes serious incidents fatalities employee health safety programmes human rights environment community investment data summary gsk corporate responsibility report employment practices gsk employs people countries goal best place best people best work central business strategy key business success aim create positive working environment offer competitive reward packages emphasise performance provide opportunities training advancement listen respond employee feedback see annual report details business strategy expect employees meet high standards way conduct global leadership survey every two years carry work gsk gsk spirit defines managers took part last survey culture principles expect employees results showed significant improvement work items compared results details results see corporate responsibility report performance integrity survey findings reviewed gsks corporate executive entrepreneurial spirit team business units implemented action focus innovation plans deliver improvements key areas example gms extended core leadership edge programme sense urgency leaders increased focus staff passion achievement development including mentoring coaching rd implemented quarterly pulse employee regular performance appraisals assess whether employees survey understand better opportunities upheld principles requirements enhance employee engagement satisfaction code conduct work see ethical conduct also launched focus patient initiative code results affect bonuses career build strength putting patient first progression plans decision making section explains approach performance activity covers conduct range interim employee surveys gauge regular employee surveys satisfaction motivation engagement programmes recruit retain diverse leadership surveys workforce annual us inclusion resilience poll sent employee development performance appraisals us employees survey gathers talent management feedback worklife resilience issues progressing towards diversity vision scores communicate employees get diversity higher results included feedback health safety wellbeing programmes favourable question employee surveys would rate overall sustainability business rests factors satisfaction gsk difficult measure quality leadership present time culture ability develop talented people regular employee surveys help us monitor evolution feel valued employee gsk gsks culture overall employee satisfaction manager enables flexible results used assess effectiveness people innovative solutions managing management practices identify areas work personal life improvement work environment enables maintain healthy lifestyle gsk corporate responsibility report employment practices continued diversity gender diversity worldwide gsk committed employing diverse workforce women management positions held environment employees treated respect grades women dignity diversity benefits business workforce diverse backgrounds cultures outlooks helps us ab bands understand needs different patients customers c c delivering genuine equality opportunity sure best people right jobs c c best work gsk total management grades range initiatives ensure meet corporate executive team senior vice presidents vice presidents diversity commitments also monitor report data director level gender diversity management grade worldwide manager level ethnicity uk us background information see website women remain underrepresented senior grades continue focus ways ensuring women activity performance genuine equality opportunity gsk annual us inclusion resilience poll includes hold women science event uk year questions diversity rated higher enabling female science graduates give feedback gsk could attract women scientists similar respondents agreed senior management event launched us may attended shows actions creating inclusive female male employees focus environment top priority gsk compared development women scientists gsk thought workgroup climate diverse perspectives valued compared thought manager demonstrates ability manage diverse workgroup compared gsk received score corporate equality us human rights campaign foundation measures companies treatment gay lesbian bisexual transgender employees consumers investors companies scoring percent included organisations best places work glbt equality list gsk corporate responsibility report employment practices continued ethnic diversity people color employees people color us employee population ethnic minorities employees uk employees ethnic minorities gsk corporate responsibility report employment practices continued us people colour made employee development talent workforce compared uk management ethnic minorities defined uk commission gsk invests training development enable racial equality accounted employees employees perform best ability compared cr report develop careers talent management processes wrongly reported number ethnic minority help us identify develop leadership candidates employees due error data collection system corrected training provide jobrelated training courses employees multicultural marketing diversity awards leadership training managers employees enrol annual multicultural marketing diversity awards training programmes mylearning intranet recognise staff found creative ways reach site uk us employees wider audience employees customers attended development programmes communities awards given several categories countries similar opportunities exist employees including one employee attraction development worldwide data currently collected retention years winners included takeup programmes uk rd residential chemistry training experience people attended leadership edge global designed increase diversity candidates programme senior managers attended attracted chemistry roles final year undergraduates leadershipgsk programme middle managers spent week gsk programme ran five inspirational leadership workshops attended applications particularly sought ethnic executives senior leaders significant minority students nontraditional universities influence large numbers staff focus gsk recruits participants received coaching senior leadership role inspiring motivating people technical personal professional subjects high performance meet business challenges interacted gsk employees levels employees attended foundation niquitinteam birmingham uk raised programme new managers managementgsk awareness smoking cessation among ethnic programme designed help managers improve populations higher average smoking performance staff increase insight rates differing work styles strengths motivation us consumer healthcare hispanic employee development network worked number gsk brands regular performance appraisals reward strong help understand improve appeal performance help employees set objectives hispanic community included sensodyne identify training need twothirds brand networks input increased sales gsk employees receive annual performance appraisal hispanic community compared performance development planning general market increase pdp programme employee networks pdp includes assessment well employees employee networks include programmes asian implemented gsk spirit principles use african american hispanic gay lesbian employees define culture significant impact provide forum employees similar bonus payments potentially reducing zero backgrounds meet discuss issues shared concern employee found followed spirit set gay lesbian staff network uk also affect future career development simple reason enable positive inclusion lesbian gay talent management bi transsexual staff gsk culture team work identify highest performing employees essential requirement modern pharmaceutical business function annual talent industry exclusion grounds sexuality sexual management cycle talented individuals take part orientation obstacle effective team work leadership programmes exposed top personal development management programmes chief chair founder gsk rd uk glsn executive forum gsk corporate responsibility report employment practices continued pool potential successors identified vice consult employees changes affect president senior management positions discuss business developments works reviewed annually appointments subcommittee councils european employee forum board similar forums countries national practice european employee forum internal communication discussed topics including transformation optimisation programme europe proposals good internal communication important achieving change gsks european distribution supply business objectives well creating open chain companys approach stress inclusive work environment range workplace new uk information consultation communications channels keep employees date forum established address company news enable give feedback strategic level business developments company include proposals change areas employment mygsk global intranet site provides news policy pensions updates qa section employees put townhall sessions employees levels questions directly ceo senior company hosted senior management executives jp garnier gsks chief executive employees opportunity discuss progress answered questions behind news section business raise questions give feedback gsk intranet gives companys position important issues linked press stories gsk also keep employees informed corporate mygsk updated ensure responsibility cr copies cr employees access news policies overview brochure distributed employees directly spirit magazine online cr survey webbroadcasts gsk senior management sent randomly selected gsk employees assess including executive team members awareness approach cr cr reporting see employees major sites february gsks ceo stakeholder feedback chairman head rd hosted global broadcast viewed employees sites developing internal communication initiative employees completed followup survey ethical leadership role every employee agreeing broadcast increased protecting enhancing gsks reputation understanding gsks priorities beyond launched include elearning module second broadcast december celebrated year guidance managers facilitating discussions gsks vaccine shown venues ethics policies team new material recognised employees made outstanding mygsk contributions company track effectiveness communications spirit internal magazine reaches around questionnaires employee surveys monitor employees throughout company four times year questions employees put senior managers many sites also produce local newsletters qa pages mygsk ensure pick potential confidential feedback mechanisms enable employees areas concern also track readership news stories raise concerns include integrity helpline see mygsk help improve relevance interest ethical conduct content employee surveys carried regularly throughout organisation see employee surveys conduct next biannual leadership survey gsk corporate responsibility report employment practices continued health safety consumer research development sites well seven distribution centres eight major office locations health safety employees contractors approximately smaller offices sales absolute priority gsk programmes locations include available data sites systematically assess risks associated operation part year notes attached operations monitor performance causes charts explain scope data collection process incidents aim assess learned take parameter detail also include data action protect employees others workplace injuries illness number suppliers need improve implementation sites provided information aim eliminate workrelated injuries verification illnesses ii main measure number cases resulting time work losttime cases target environment health safety sections last years reduce number per report externally verified erm hours worked every year achieved environmental resources management target average first two years rate web pages verification applies remained almost constant since indicated symbol erms verification meet fiveyear target statement setting new ii target part manage health safety plan excellence set targets manage health safety integrated reportable ii cases gsk defines serious environment health safety ehs management first aid may also reported system system incorporates ehs employee government regulations countries safety theory health policies ehs vision global ehs standards suggests addressing reportable ii help ehs plan excellence sets strategy eliminate risks hazards lead fewer improving ehs performance currently reportable cases well losttime ii cases renewed extend health safety section corporate environment health safety cehs report employee health management ehm teams help section contains information manage coordinate health safety programmes health safety part overall ehs management pages summarise activities describes programmes reports injury illness relate specifically health safety see ehs rates highlights serious incidents fatalities covers management pages information manage health safety audits gsk operations environmental broader ehs issues programmes cover wide range hs aspects training awareness providing safety training sales employees tend ehs training targeted match employee highest number fatalities working responsibilities employees responsibility hs employees improve general health issues receive regular training initiatives areas th year reported health ergonomics chemical exposures driver safety safety performance legacy companies glaxo handled regional meetings hs staff wellcome smithkline beecham individually published turn train employees manufacturing research ehs reports number years prior formation sales divisions cehs ehm arrange annual gsk copies reports available meetings determine training issues provide corporate register website training materials wwwcorporateregistercom also want employees aware health scope data safety personal lives employee bulletins health safety data covers calendar year announcements myehs website ceo 's ehs collected pharmaceutical excellence awards programme health safety consumer manufacturing sites seven eight biologicals week activities aim raise employee awareness issues manufacturing sites pharmaceutical wearing seat belts careful electricity using ladders appropriately gsk corporate responsibility report employment practices continued conduct health safety week every october also introduced continued specific work coincide european health safety week following areas achieve improvements fire safety awareness month united states chemical agents targets set within manufacturing information kits sent sites help develop promoting accurate exposure determinations ideas plan activities ensuring adequacy respiratory protective employees sites equipment unit operations discussions countries took part health safety week presentations network meetings activities included sports days safe driving education resilience rollout tool assessing team ergonomics training awarenessraising noise resilience training ehs network meetings safeguarding hearing healthy eating lifestyles family participation events ergonomics training ergonomic risk assessment network meetings well regional training health safety feedback ehs audits risk assessment guideline revised aim conduct ehs audits operational site aligned risk assessment requirement least every four years carry frequent quality group visits selected sites depending assessment risk issues raised previous audits self audit training workshop selfauditing conducted ehs network meetings end assessed performance facilities except small commercial sites using self management system elements rollout assessment internal audit audited sites management system toolkit described average score sites achieving score sites required develop plans address regard unacceptable weaknesses potential improvements identified average score exceeds target aim audit auditors monitor sites progress correct unacceptable performance continue pursue implementing plans auditors trained improvements achieve best practice findings compared ensure consistency continued refine ehs audit process scoring audits identified several priority areas system based experience feedback also chemical exposure risks installed ehs auditing software intranet help chemical risk assessment control sites auditors track progress managing resilience mental wellbeing ohsas certification two additional sites achieved certification ergonomic risk assessment control international health safety standard ohsas scope adequacy workplace risk assessments brings total number manufacturing sites selfauditing health safety programmes certified pharmaceutical consumer vaccine manufacturing sites one additional site management systems implementation certified utilities area certified sites aim drive improvements poorlyperforming areas china egypt france india kenya mexico poland saudi actively tracking audit findings identifying arabia turkey uk see audits certification improvements followup audits sites scoring less information certification environmental also provide increased support management standard iso audit team including followup visits ensure progress discussions senior business management increased site resources many sites require several years put adequate systems programmes place areas gsk corporate responsibility report employment practices continued excellence awards drums solvent per year reduced risk chief executive officers environment health solvent spilled well reducing cleaning safety ehs excellence awards recognise reward disposal requirements waste drums pallets innovation gsk sites winning entries musculoskeletal injuries reported ehs initiative health safety category incidents involving chemical burns solvent splashes time metering system introduced first placebarnard castle uk proven capability award given shirt sleeve working environment see ceos ehs excellence award website site moved toward controlling operator exposure awards programme winners previous highly potent compounds using containment years routine tasks rather using respiratory protective equipment guard exposure ehs considerations injury illness rates causes integrated sites business model main measure injury illness number introducing new products allowed incidents result one days away containment integrated design work lost time express rate per manufacture hours worked second placewavre belgium sobane target reduce losttime rate innovative approach safety year end fact rate improved since suggests reached wavre introduced new approach safety management plateau effectiveness prevention significantly reduced number programmes injuries one three gsk biologicals sites belgium involved research development production renew efforts improve effectiveness vaccines programmes also focus reportable injuries illnesses result time work site speciallydesigned building reportable incidents serious first aid even employees work filling vials syringes though result day work safety vaccines seven losttime injuries experts believe addressing causes less building first nine weeks serious injuries result improvements five accidents resulting disability type categories injuries sustained getting significantly worse ehs department responded introducing new safety also measure number days lost injuries management methodology known sobane illnesses provides indication severity incidents although rough guide sobane method involves active participation example illness could lead permanent hearing loss staff screening potential safety risks finding disability without resulting significant lost time solutions every member staff becomes member team active safety role main data covers gsk employees contract workers directly supervise separately report method introduced may resulted data contractors work gsk sites supervise potential safety risks solved staff staff data covered erm may may lost verification time injuries days passed without accident resulting disability causes injuries illnesses injuries without lost time arise mainly slips method since expanded gsk biological trips falls overexertions strains motor vehicle sites belgium plan introduce gsk accidents biological sites around world losttime illness stems mainly mental illhealth third placecork ireland bulk solvent metering musculoskeletal problems primarily repetitive strain injury research development pilot plant musculoskeletal illness main cause reportable introduction bulk solvent metering cork illness lead days work accounting pilot plant eliminated need handling almost third total gsk corporate responsibility report employment practices continued mental illhealth approximately illnesses resulted cases workrelated mental ill health excluded permanent disabilities noiseinduced hearing overall illness rate consistency loss sensitisation chemicals musculoskeletal reporting cases less robust occupational illnesses illnesses variations way illnesses gsk 's injury illness performance placed us third defined local legislation affects reporting quartile benchmark industry group working address inconsistencies aim include cases future mental ill causes injuries illnesses health rate involving lost time per main causes injuries motor vehicle accidents hours worked mental illhealth second slips trips falls illnesses leading lost time significant cause workrelated sickness absence mainly musculoskeletal concerned mental ill accounting days total health chemicalrelated dermatitis following exposure chemicals work caused significant number illnesses information programmes reduce illness lead lost time injury see health programmes safety programmes record highlights workplace injury illness incidents sites countries lost time injuries illnesses year addition gsk employees contractors one site india achieved million hours worked injuries illnesses without lost time injury illness incidents leading one site singapore achieved million hours worked lost time without lost time injury illness musculoskeletal six sites canada china india pakistan achieved included million hours worked without lost time injury mental illness illness included fourteen sites china france india mexico pakistan days lost philippines south africa uk us achieved excluding mental illness million hours worked without lost time injury illness reportable incidents performance leading lost time table summarises experience charts illustrate trends musculoskeletal included recorded injuries illnesses compared respectively mental illness employees lost working days incidents included comparing record expected relationship incidents result lost time contractor data included verification erm dont suggests undercount real number injuries illnesses result lost time working improve reporting injuries illnesses gsk corporate responsibility report employment practices continued lost time injury illness rate injury illness lost time injury illness rate year illness injury total dekrow sruoh rep gsk corporate responsibility report employment practices continued reportable injury illness without lost time rate injury illness dekrow sruoh rep reportable injury illness without lost time rate year illness injury total gsk corporate responsibility report employment practices continued lost time injury illness business primary nu dp p al ny tibiotics ew product g la bd l supply egional pharma supply umer healthcare supply biologicals researc dh ea ven ld opment commercial n r n c lost time injury illness business ii rate primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial dekrow sruoh rep gsk corporate responsibility report employment practices continued reportable injury illness without lost time business primary nu dp p al ny tibiotics ew product g la bd l supply egional pharma supply umer healthcare supply biologicals researc dh ea ven ld opment commercial n r n c reportable injury illness without lost time business ii rate primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial dekrow sruoh rep gsk corporate responsibility report employment practices continued calendar days lost rate injury illness calendar days lost rate year illness injury total dekrow sruoh rep gsk corporate responsibility report employment practices continued categories lost time injury contact sharp objects caught inonbetween slipstripsfalls striking againststruck overexertionsstrains motor vehicle accidents slipstripsfalls motor vehicle accidents overexertionsstrains striking againststruck caught inonbetween contact sharp objects burnsthermalchemical foreign bodiesobjects workplace violence electricalfireexplosion animalinsect total gsk corporate responsibility report employment practices continued categories lost time illness infection musculoskeletal mental health musculoskeletal mental health infection nonallergic respiratory allergic respiratory nonallergic dermal systemic allergic dermal physical cancer reproductive total gsk corporate responsibility report employment practices continued categories reportable injury without lost time overexertionsstrains burnsthermalchemical caught inonbetween slipstripsfalls motor vehicle accidents striking againststruck contact sharp objects overexertionsstrains slipstripsfalls striking againststruck contact sharp objects motor vehicle accidents caught inonbetween burnsthermalchemical animalinsect foreign bodiesobjects electricalfireexplosion workplace violence total gsk corporate responsibility report employment practices continued categories reportable illness without lost time mental health allergic respiratory infection nonallergic respiratory musculoskeletal allergic dermal physical nonallergic dermal musculoskeletal nonallergic dermal physical allergic dermal nonallergic respiratory infection allergic respiratory mental health systemic cancer reproductive total gsk corporate responsibility report employment practices continued summary tables lost time injury illness lost time injuries lost time injuries illnesses lost time rate per illnesses rate lost time injuries illnesses per year injury illness hours worked injury illness without lost time injuries without lost time illnesses without lost time injuries illnesses without lost time per hours worked calendar days lost injury illness lost days injuries days lost illnesses calendar days lost per hours worked injuries illnesses without lost time rate per year injury illness notes charts health safety data cover employees contract workers directly supervised gsk employees injury illness rates per hours worked lost time injuries illnesses workrelated injuries illnesses serious enough result one days away work calendar days lost rate per lost calendar days calendar days year injury illness employees could work workrelated injuries illnesses helps provide measure severity injuries illnesses reportable injuries illnesses without lost time reported incidents result time away work lost time serious first aid generally less serious lost time include cases mental ill health lost time reportable illness rates supplier health safety performance variations way mental illhealth defined reported across sites globally working requested information suppliers address includes contract manufacturers key suppliers provided data provided data comparative figures suppliers reported total million work hours gsk corporate responsibility report employment practices continued serious incidents fatalities employee health deeply regret one employee died work workplace culture supports healthy resilient related driving incident egypt two members workforce drives positive business performance protecting public killed driving accidents promoting wellbeing employees increases involving gsk employees employee productivity attendance reduces health care health insurance costs supports us working reduce traffic related accidents goal employee choice aligned driver safety programme see safety programmes gsks mission improving quality life seen reduction number workrelated sections focus steps fatalities last years consistent taken improve ergonomics resilience managing targets improving health safety performance set pressures stress attendance also provide plan excellence contractor fatalities information hiv initiatives planning process remained largely constant period potential worldwide influenza pandemic five year trend employee fatalities health programmes fatalities health programmes enable employees families benefit better health enhanced quality life business gains increased employee commitment productivity reductions financial impact illhealth range programmes support employee wellbeing including onsite health fitness centres flexible working arrangements family support services healthcare benefits focus prevention also report serious incidents ie incidents result access innovative proven treatments example permanent disability reported us employees receive free immunizations cancer regulatory authorities accidents involving screening help smoking cessation regular check machinery resulted three employees sites south ups assist employees suffering chronic diseases africa us puerto rico suffering finger medical plans provide support help amputations one contract temporary worker site continue treatments us lower leg amputated result developed scorecard measure track forklift incident twenty two employees progress improving employee health adding value evacuated site france following accidental business scorecard contains quantitative release hazardous chemical nine needed medical measures including illhealth absence rates report treatment eight hospitalised night performance measures targets one sales employee us involved multi vehicle road accident resulted severe injury hospitalisation employee uk suffered burns held five workshops globally environment body result burst pipework releasing health safety human resources share boiling water steam information best practice employee health management department supports sites across gsk investigate circumstances fatalities implementing employee health policy achieving serious incidents assess learned consistent standards carry internal audits reduce risks also issue global alerts posted monitor site performance oversee improvement plans intranet site communicate information could help prevent similar incidents sites ergonomics musculoskeletal illness injury one leading causes ill health resulting time away work appointed fulltime professional ergonomist lead development ergonomics strategy set target reduce number ergonomic gsk corporate responsibility report employment practices continued illnesses injuries improving workplace team resilience programme participatory job design also improve efficiency proactive quality improvement process utilizing productivity assessment tools identify sources workplace stress teambased solution focused process looks internal ergonomics university established issues cause pressure affect performance increase knowledge ergonomic issues work demands team relationships management best practice among gsk employees introduced practices career development concerns work computer presentations variety ergonomic topics culture individual team members get confidential cdbased programme commercial fieldbased personal profile tailored action plan developed employees covering ergonomics go global whole team staff took part team ergonomic community website developed resilience programmes programme employees discuss issues share ideas access translated spanish portuguese french german resources includes best practice examples ranging italian japanese mandarin laptop ergonomics lifting majority gsk sites programmes reduce launched online ergonomics risk assessment workplace pressures help employees achieve good officebased employees help reduce ergonomic injuries worklife balance include time management associated computer use programme used training flexible working options health awareness gsk sites worldwide translated education initiatives employees spanish french italian polish worldwide access employee assistance employees completed computerbased risk programmes provide confidential support hours assessment developing similar risk assessment day along additional counselling needed tool nonoffice based employees piloted us manufacturing sites team resilience programme received external recognition uk health safety executive established employeeled ergonomic hse nominated several awards improvement teams manufacturing sites uk included winning personnel todays managing health us latin america role embed ergonomic work award design considerations workplace practices procedures example team zebulon site attendance us made number improvements work longterm employee absence financial impact environment include use adjustable height gsk lost productivity efficiency limiting carts reduce injuries lifting heavy items employee absence helping work return rolls material also reduces waste due reduced soon appropriate minimise costs manual handling materials launch improve employee wellbeing ergonomic improvement teams manufacturing facilities launched new case management approach across europe asia longterm employee absence uk involves resilience close collaboration ehm team hr staff line mental illness another one leading causes managers employees key elements ill health resulting time away work use include accurately measuring absence ensuring term resilience describe set skills behaviours maintain regular contact employees needed successful highly pressured fastpaced work make sure employees doctors continuously changing environment enables know widerange inhouse support available us support employees manage work home gsk including access physiotherapists counsellors demands effectively minimises adverse occupational health physicians health affects stress data resilience rehabilitation plan agreed employee programmes show improve business results may include making modifications workplace along employee commitment engagement reducing work hours finding alternative work programmes fully support uk legislative fully recovered requirements tackle sources workplace stress gsk corporate responsibility report employment practices continued initial results suggest approach led fall team developed global policy plan gsk absence rates several sites approximately business continuity employee health preparedness around years estimated one plan minimises impact pandemic manufacturing site uk experienced cost savings employees ensures able continue million based direct indirect manufacturing medicines vaccines costs absence employees returning work safety programmes quickly signed longer systematically assess risks anticipate potential necessary staff feedback indicates majority accidents put programmes place minimise employees feel betterinformed valued supported learn investigating causes accidents continue roll new make improvements accordingly section procedures across sites uk plan cover three key areas driver safety process safety complete process mid target uk chemical exposure reduce number days lost due longterm information approach ergonomics see absence set target employee health manufacturing sites worldwide achieve least attendance driver safety sales representatives drive long distances every year hivaids therefore particularly risk involved provide antiretroviral treatment arv hiv workrelated road traffic incidents positive gsk employees full parttime driving accidents resulting lost time families developing world treatment accounted losttime injuries provided adequately consistently local healthcare system global ehs standard occupational travel includes requirements driver safety developed offer preferentially priced arvs employers technical instruction documents help gsk businesses subsaharan africa provide care treatment comply standard cover topics staff see preferential pricing training vehicle selection risk assessment accident developed awarenessraising initiatives use reporting driving environment worldwide educational materials developed combined documents additional safety gsk kenya positive action programme guidelines create compliance tool commercial wwwgskcompositiveaction adopted businesses called ehs essentials companies kenya reaching estimated approximately gsks commercial businesses employees public private sectors materials extensive driver safety programmes place include translated french available driving licence checks guidance use mobile companies burkina faso cameroon chad gabon phones vehicles driver safety training tracking madagascar mali early materials reporting incidents working ensure sites translated arabic help companies high standards place morocco gsk mexico gsk dominican republic develop similar spanishlanguage resources use countries provide motorbikes scooters central america gsk india also started process employees produced gsk motorbike rider three employee workshops hiv aids safety manual translated distributed pilot survey demonstrating need employee employees countries bangladesh india hiv education indonesia pakistan vietnam countries also fully implemented gsk requirement influenza pandemic every driver motorbike wear helmet global outbreaks avian influenza bird flu continue follow monitor implementation highlighted danger potential worldwide influenza motorbike safety programme pandemic externally working governments assist provision development antiviral drugs vaccines manage potential pandemic internally cross business gsk corporate responsibility report employment practices continued process safety safety engineering commissioned benchmarking study process safety programme ensures safety containment methods potent chemical compounds built manufacturing research development seconded member engineering staff processes programme based hazard corporate ehs work ensuring relevant identification control risk assessment operations engineering controls expanded risk assessment tools evaluations new product support process designed rate system includes tools covering failure integrate ehs considerations product design teams mode effects analysis hazard operability failure include product stewardshipoccupational toxicology mode effects criticality analysis programmes apply expert whose role ensure chemical exposure globally allowing us standardized assessment ehs considerations built product documentation share safety information across design business sectors launched initiative ensure primary supply antibiotics supply chain updated safety plans focus key risks regulatory compliance material hazard information hazclass system tracks hazardous material shipments worldwide monitors transportation materials per month developed safety data sheets sdss products pharmaceutical products sold us europe available website wwwmsdsgskcom email notification tool automatically keeps employees todate changes sdss started make environmental testing data available sdss occupational hygiene control chemical exposure exposure chemicals resulted respiratory skinrelated losttime incidents cases result lost time together accounted workrelated illnesses developed strategy control chemical exposure sets plan action achieving goal shirt sleeve working environment workplace contain chemicals using engineering controls manufacture employees need wear protective equipment introduced several steps help us achieve goal began recruiting regional hygienists deliver improved occupational hygiene oh service businesses began design dispensary equipment powdered pharmaceutical ingredients eliminates need protective equipment human rights introduction access medicine research ethical conduct employment practices human rights employee human rights supply chain human rights environment community investment data summary gsk corporate responsibility report human rights human rights broad subject relevant gsk number different contexts section discuss human rights gsk employees human rights supply chain information preferential pricing arrangements hivaids medicines see access medicines direct employees well educated standards via selfassessment questionnaire skilled people striving make audit identify human rights issues company attractive employer generally workforce employment standards issues diversity equal confirm gsk employ children opportunities health safety provide adequate anyone younger employees entitled safeguards human rights employees join trade unions organise countries supply chain complex diverse global permitted national legislation committed recognise possible suppliers countries listening responding views employees fully respect human rights workers including works councils staff consultation local communities within sphere influence committees see internal communication begun work ensure suppliers observe discrimination harassment tolerated similar standards relations employees circumstances employees report concerns communities senior management confidential basis using risk human rights issues occurring global integrity helpline cases significant gsk companies reported employees compliance function industries nevertheless several reasons directly raised human rights issues need take human rights seriously achieving high standards human rights supports reputation supply chain human rights goal operational excellence helps us get best employees working suppliers supply chain complex suppliers match standards help ensure smooth worldwide ranges major strategic relationships operation supplier contracts therefore reliable suppliers manufacture raw materials supply high quality products packaging gsk medicines local contracts goods services office equipment cleaning security employee human rights endeavour ensure suppliers follow human rights employees work protected high standards human rights apply gsk employment policies procedures given size global scope supply chain details see employment recognise suppliers may fully respect operate globally including countries human rights workers local communities government fully respect human rights started work suppliers issues believe presence countries vital ensure inclusion human rights clauses supplier continued access medicines people aim contracts see next create workplace employees countries standards match operations also cover human rights issues routine elsewhere thereby contribute improving interactions two categories critical suppliers employment practices generally contract manufacturers make gskbranded medicines consumer health products suppliers raw conduct annual human rights employment audit materials packaging manufacturing sites make sure delivering commitment historically suppliers tended based international human rights standards head human europe north america growing trend resources country operate required towards sourcing materials areas report whether gsk employment practices meet gsk corporate responsibility report human rights continued world asia visit critical suppliers regularly suppliers providing goods used make gsk review performance identify resolve branded products eg contract manufacturers raw issues including potential human rights issues materials packaging interactions include suppliers providing human resources eg cleaning preassessment potential new critical suppliers services security services contingent worker services questionnaires onsite reviews quality outsourced services testing research development ehs audits assessments cover facilities services directly supply gsk scope eventually extended contracts ongoing critical supplier reviews include followup engagement critical suppliers visits procurement quality ehs staff also hold global regional supplier review meetings critical suppliers must work highest quality senior gsk managers address interact standards produce uninterrupted supply suppliers key issues materials services gsk safety effectiveness availability medicines could important procurement teams understand affected reasons seek longterm human rights standards provide training relationships critical suppliers regularly monitor guidance human rights gsk procurement staff aspects performance including human rights part sourcing group management programme explains develop sourcing strategies critical suppliers must pass detailed assessment criteria supplier selection including human rights selected well looking quality issues training compulsory new procurement staff also assess policies procedures health safety human rights environmental issues given size complexity supply base rigorous assessments reduce risk issues possible engage directly suppliers non compliance contract signed human rights well routine engagement suppliers meet required standards critical suppliers start pilot project work agree remedial programme assess risk human rights issues occurring among must implemented completed award suppliers services large labour input new business contract manufacturers must example cleaning security also approved applicable regulatory authority also engage suppliers environmental health start manufacturing gsk medicines safety issues see environment working contract awarded seek ribena suppliers improve biodiversity develop strong open relationships critical suppliers supplier contracts includes formally agreed supplier reviews adding human rights clauses supplier assess performance identify agree areas contracts require suppliers confirm improvement supplier review agreed action comply minimum wage legislation provide healthy plan signed gsk supplier safe workplace free discrimination use supplier cant wont improve performance form slavery exploitative child labour move business alternative supplier far incorporated human rights clauses launched preferred global vendor programme central contract templates use new suppliers reduce number suppliers well reducing human rights clauses also introduced costs increasing efficiency make easier contracts existing suppliers renewed monitor influence supplier standards contracts renewed threeyear cycle supplier audits worked local procurement conduct regular environment health safety teams incorporate human rights clauses local audits contract manufacturers include supplier contracts given size supply chain questions human rights prioritised contracts human rights audits conducted human rights issues clause must inserted initial focus significant concern noted gsk corporate responsibility report human rights continued gsk supplier human rights clauses human rights clause based international workplace norms international labour organisation conventions uns universal declaration human rights text sets standard englishlanguage version contract clause must noted exact wording may vary contracts gsk attorneys may amend wording hr clause negotiation third parties translation suit local law however gsk attorneys instructed change human rights clause way reduces contractual impact intent gsk standard contract clause ethical standards human rights ethical standards human rights unless otherwise required prohibited law f pays employee least minimum wage supplier warrants best knowledge fair representation prevailing industry relation supply goods services wage whichever higher provides terms agreement employee legally mandated benefits ait employ engage otherwise use git complies laws working hours child labour circumstances tasks employment rights countries performed child labour could operates reasonably foreseen cause either physical hit respectful employees right join emotional impairment development form independent trade unions freedom child association bit use forced labour form supplier agrees responsible controlling prison indentured bonded otherwise supply chain shall encourage employees required lodge papers compliance ethical standards human rights deposits starting work subsequent supplier goods services c provides safe healthy workplace used supplier performing obligations presenting immediate hazards employees agreement housing provided supplier supplier shall ensure ethical employees safe habitation supplier human rights policies appropriate complaints provides access clean water food procedure deal breaches policies emergency healthcare employees event accidents incidents supplier 's gsk reserves right upon reasonable notice unless workplace inspection cause case notice shall necessary enter upon supplier 's premises dit discriminate employees monitor compliance supplier warranties ground including race religion disability set clause supplier shall gender subject compliance law furnish gsk eit engage support use relevant documents requested gsk relation corporal punishment mental physical sexual thereto subsection required verbal abuse use cruel abusive general right audit elsewhere within disciplinary practices workplace agreement environment introduction energy global warming potential energy consumption access medicine transport research water water use ethical conduct wastewater employment practices waste human rights hazardous waste nonhazardous waste environment recycling introduction nonroutine waste erm verification statement ozone depletion gsk response ozonedepleting substances environmental management manufacturing plan excellence ozonedepleting substances audits certification ancillary equipment stakeholder engagement volatile organic compounds training awareness biodiversity ehs excellence awards suppliers progress towards targets materials efficiency community investment product stewardship data summary product design pharmaceuticals environment metered dose inhalers gsk corporate responsibility report environment year completed first five years environment health safety ehs plan excellence marks important milestone journey environmental sustainability environmental performance reported pages health safety performance reported employee section introduction ehs structure includes set stretch targets consultation management system based set global business address ehs issues concern standards incorporated framework ehs stakeholders set targets identified programmes proposed improvement projects would help us ehs plan excellence identifies achieve specific underpinning tenyear strategic vision ehs gsk projects achieve environmental targets ceos ehs excellence awards recognise performance outstanding projects gsk sites around world achieved many ehs targets met link excellence awards document surpassed targets energy consumption related carbon dioxide emissions water consumption feel made significant progress wastewater organic material measured chemical improving performance ehs gsk realise oxygen demand nonhazardous waste ozone always first need embed depleting substances used produce inhalers culture people really understand business benefits good ehs practice enhanced productivity volatile organic compound voc emissions air quality employee relationships beneficial achieved significant reduction almost achieved gsks performance reputation ambitious target reduction investors also set ambitious target ozone depleting already understood investors appreciate compounds ancillary equipment achieved progress transparency means improvement open areas done cases changes business helped us make well planned progress eg wastewater quality emissions solvents borne positive ratings gsk air two cases hazardous waste disposal receives various investor ratings recycling changes made progress difficult meet targets areas due factors gsk recognized indices maintenance recycling systems movement products dow jones sustainability index djsi production facilities without recycling equipment djsi members top per cent industry new product introduction sector selected largest provide details performance area companies world selection based best performance pages section inclass approach covering economic social environmental criteria ehs management solid foundation programmes management business environment index premier league systems contributes progress made gsk third consecutive year gsk moved towards describe selfregulatory listed premier league achieving score ehs culture focuses first achieving legal per cent data index rates environmental compliance manages ehs proactively based management environmental performance understanding risks liabilities opportunities carbon disclosure project 's climate leadership part strategic objectives achieve operational indexgsk one three pharmaceutical excellence responsible company companies named climate leadership index carbon disclosure project coalition gsk corporate responsibility report environment continued institutional investors trillion energy conservation assets climate leadership index includes longer term see three possible steps companies well positioned respond becoming environmentally sustainable business financial implications climate change compared ft peers improve natural resource efficiency decrease amount waste generate looking ftsegood ftsegood index series broadly production include efficiency includes companies meet globally recognised operations link materials efficiency corporate responsibility standards facilitates investment companies move relying nonrenewable chemicals renewable materials sustainable companiesgsk one four pharmaceutical companies identified move using synthetic chemical routes biological global sustainable corporations systems create medicines world project initiated corporate knights take many years achieve transition innovest strategic value advisors leading part journey towards environmentally research firm specialising analysing non traditional sustainable company drivers risk shareholder value covering performance social environmental strategic james hagan governance issues launched annual vice president global announced year world corporate environment health safety economic forum davos environment section report ratings like help investors identify companies th year reported meet investment goals important environmental performance legacy companies glaxo gsk 's reputation achieved proactive wellcome smithkline beecham individually published approach ehs sustainability companywide ehs reports number years prior formation reporting ehs performance data index listings gsk copies reports available tribute many ehs professionals corporate register website managers staff gsk sites report wwwcorporateregistercom data listing based background information approach investors stakeholders also appreciate managing environmental issues available commitment dialogue much appreciate environment health safety section website value stakeholders perspectives wwwgskcom created formal stakeholder panel also note scope data consulted widely gsk people move next environmental data covers calendar year fiveyear plan period collected pharmaceutical future consumer manufacturing sites six eight biologicals internal external engagement helped us focus manufacturing sites pharmaceutical major challenges immediate future consumer research development sites well seven distribution centres six eight major office occupational exposure chemicals see occupational locations four smaller office sales locations hygiene nn include available data sites operation driver safety see nn part year process safety see nn notes attached charts explain scope data pharmaceuticals environment see nn collection process parameter detail unless specified per unit sales figures absolute hazardous chemicals usage numbers ie total consumption energy water etc gsk corporate responsibility report environment continued verification overall assessment environment health safety sections subject scope assessment comments report externally verified erm environmental set believe gsks ehs reporting resources management pages corporate responsibility report complete relevant verification applies indicated accurate representation gsks performance symbol erms verification statement review made following findings response follow recommendations findings erm verification statement reporting year gsk reported progress environmental resources management limited erm five year performance targets set key areas appointed gsk undertake external verification environment health safety found gsk assessment environment health safety ehs made good progress strengthening internal reporting reporting within gsk corporate responsibility processes better understanding reasons ehs report section environment health performance change targets safety pages within employee practices section gsk provides wide range information report fifth year involvement external always clear material issues facing verifier gsk objectives assessment business found inconsistency level detail check ehs data presented accurate provided reasons performance change example represent gsks performance fairly critically changes major contributing sites significantly review completeness relevance information affect group total presented assess effectiveness gsks data management reporting systems pages gsks gsk improved collection data contract report contain ehs data verified erm marked manufacturers suppliers expanded following symbol number contract manufacturers collects key ehs data ongoing challenges collecting complete accurate data gsk able report broader ehs footprint one recommendations related limitations ehs performance data particular scope assessment potential scale statistical uncertainty period october february consideration gsk report conducted following tasks consistently cover significance potential limitations assessments six globally significant sites data calculation method robustness telephone interviews additional sites review sampling techniques understanding performance ehs data management reporting processes change example calculating voc emissions review corporate data collation internal data accuracy verification processes gsk offices uk gsk continued make progress improve review content ehs sections accuracy ehs data introducing internal corporate responsibilityreport including checking data checks globally significant sites erm sample group data assess completeness identified number material data inaccuracies relevance accuracy assessments site level checking sample group data part due changes reporting schedule interviews corporate personnel obtain introduced meet deadlines supporting information gsks ehs performance corporate reporting program inaccuracies following areas acquisitions divestitures subsequently addressed gsk ensure accurate contaminated land auditing gsk sites suppliers reporting corporate responsibility report contract manufacturers hs reporting relating us sales force setting performance targets gsk corporate responsibility report environment continued improvements energy performance gsk response verification statement following introduction businessspecific energy verifying gsks ehs reports five years many management programme also helped erms recommendations point improvements ensure accurate data reporting gsk rolling work every year example every year improve new system functions help integrate ehs management processes collecting data clarify definitions data collection instructions provide training people sites found challenges associated accurate gather enter site data improve processes complete health safety incidents reporting analysing summarising data try understand investigation site level including weakness formal changes year year internal processes check compliance gsks explain materiality requirements accurate reporting full investigation part planning process resulted incidents addition found examples year ehs plan excellence conducted misreporting due poor understanding corporate review reporting considered measures reporting requirements data entry errors ehs impact used within company used recommendations global reporting initiative surveys investment recommend gsk rating organisations environmental organizations indicators stakeholder expectations ehs reporting explains issues reports material companies size exercise business prioritises reporting accordingly concluded information metrics include reports trends outsourcing affect report material gsk decided overall ehs footprint performance expand consistent reporting five year period reporting ehs impacts contract plan excellence move next five manufacturers suppliers year period review materiality information metrics report continue improves accuracy environmental incidents report external stakeholders consider data introducing additional mechanisms check important completeness data reported sites providing additional training sites reporting data trends outsourcing management goal report aggregate ehs reviews formal processes check compliance performance contract manufacturers key gsks requirements accurate reporting full suppliers hope use report total ehs investigation incidents footprint gsk products use basis improvement targets request ehs looks opportunities align data information contract manufacturers management corporate site level integrating key suppliers every year response voluntary reporting core business processes rate low intend make response practicable questionnaire integral part future contracts erm accuracy site ehs data march comprehensive global ehs information management system place help sites manage ehs data use system collect data report internal reporting recognise past error rate initial entry varies put place thorough data verification process correct errors attempting address situation providing additional webbased training also conducting formal review information requested sites see simplified still meeting needs stakeholders gsk corporate responsibility report environment continued review processes check compliance stakeholder engagement plays important role reporting investigation incidents manage ehs carried special completed first phase audit engagement exercise employees set programme conducting comprehensive baseline standing panel external ehs stakeholders feedback review starting riskbased audit staff external sources identifies issues process include review reporting ehs data provides insights help us determine move investigation incidents part process forward also increase level training areas ceos ehs excellence awards recognise reward align corporate site data management gsk sites show leadership ehs awards conducting formal review highlight sites demonstrated exceptional information management practices identify commitment innovative approaches provide improvements made examples good practice ehs management share corporate site processes sites winners excellence awards demonstrate many projects improve environmental performance also save money environmental management carry regular ehs audits gsk operations environmental issues managed together health contract manufacturers key suppliers assess safety integrated ehs system aims extent management systems standards ensure issues risks identified standards implemented improve performance achieve established training provided targets set audits compliance conducted environment costs clearly defined ehs management structure capital investment environmental projects overall responsibility rests corporate executive million operating maintenance team board board champion ehs jp costs million expenditure relates garnier chief executive officer rupert bondy general wastewater treatment waste management air counsel operational champion ehs pollution control corporate executive team also corporate responsibility committee corporate ehs department see ehs management organisation system website ehs policy vision global ehs standards set overall framework managing issues distributed ehs management toolkit provides sites instructions descriptions appropriate procedures managers worldwide ehs plan excellence developed sets year strategy improving environmental performance came end first year period began revising extending plan gsk corporate responsibility report environment continued waste wastewater air noillim capital investment capital investment year air wastewater waste total gsk corporate responsibility report environment continued operations maintenance costs waste wastewater air operations maintenance costs year air wastewater waste total noillim gsk corporate responsibility report environment continued compliance goal ensure core programmes covering minimum aim comply legal health safety environment place requirements regret throughout global business measured breach regulations cases following uk consumer healthcare manufacturing site paid implementing operations ehs management fine court costs following system aligned iso ohsas prosecution uk health safety executive incident occurred resulted achieving acceptable audit scores amputation employees finger tip manufacturing rd operations aimed us consumer healthcare manufacturing site paid achieve average score least fine state environmental authority business unit site achieving less completing required report storage hazardous achieving year ehs global targets see progress waste towards targets puerto rico pharmaceutical manufacturing site paid analysing performance first set targets fine us environmental protection agency plan excellence result failure fully comply resource conservation recovery act formalising external stakeholder engagement process us consumer healthcare manufacturing site paid fine us occupational safety health report performance objectives administration osha related noncompliance pages osha eyewash requirements began extending plan excellence also received following notices violation aim move focus fundamental result fines penalties ehs programmes address broader environmental sustainability issues requires new approach consumer healthcare manufacturing site australia manufacturing processes measuring progress exceeding allowable limits suspended solids wastewater began review plan excellence extensive consultation key internal external two consumer healthcare manufacturing sites us stakeholders ensure relevant ehs concerns exceeding permitted substance levels wastewater needs business would reflected plan excellence extended plan ehs plan excellence set strategy improve engaged external stakeholders key ehs ehs performance tenyear period concerns expectations gsk end first five year period pharmaceutical industry taken stock begun extending plan five years undertook companywide intranet survey seeking comment discussion document reviewed developed plan following merger glaxo emerging issues business ehs wellcome smithkline beecham aligned ehs systems two parent companies laid held individual discussions selected senior approach establishing new ehs framework gsk managers parts business held workshops around world gsk 's site use annual action plans focus efforts based ehs professionals including sessions vision selected priority issues halfway point strategy corporate ehs team ten year plan important year aimed fundamental ehs managers ehs professionals told us want programmes place reach first set ehs gsk among top pharmaceutical companies targets theme year completing core area also activity must add value programmes business gsk corporate responsibility report environment continued want us work external organisations sites required develop plans address flexible embedding ehs business practices weaknesses improvements identified audit adopting approaches appropriate auditors monitor sites progress implementing business unit plans ehs audit process scoring system refined based experience feedback external stakeholders highlighted climate change including assessing auditors reports ensure greater pharmaceuticals environment policy consistency ehs auditing software available use chemicals key areas concern told us intranet help sites auditors track progress gsk forefront ehs sustainability issues exert positive influence others ehs certification industry supply chain request audit committee board directors gsk embarked programme achieve published feedback discussions iso ohsas certification three consultative document comment additional sites achieved certification international internal stakeholders gsks new ehs external environmental management standard iso two stakeholder panel see stakeholder engagement also achieved certification international health information safety standard ohsas bringing total expect publish renewed year ehs plan dual certified sites one certified site left gsk excellence mid network means pharmaceutical consumer vaccine manufacturing sites audits certification certified sites certified iso one audit programme requires manufacturing rd sites utility area certified certified sites sites audited internal auditors certified china egypt france germany india italy mexico lead auditors international environment health poland saudi arabia spain turkey kenya uk safety management standards iso ohsas assess well ehs management systems continue work increasing number standards implemented well certified sites encouraging sites volunteer sites comply key legislation revising certification also launch pilot project audit process focus significant health safety investigate feasibility certifying research risks environmental impacts frequency site development sites position audits determined factors ehs risks move towards global certification profile performance stakeholder engagement end assessed performance frequently engaged ad hoc meetings facilities except small commercial sites using self range external stakeholders help us assessment internal audit audited sites understand perspectives identify emerging average score sites achieved scores issues stepped internal external regard unacceptable engagement ehs issues average score exceeds target aim external engagement correct unacceptable performance continue pursue established standing panel external stakeholders improvements achieve best practice provide ongoing advice comment ehs two sites us spain achieved performance panel facilitated environment leadership scores seven council independent charity brings people achieved scores together develop longterm solutions environmental issues members include representatives best performance environmental issues customers suppliers regulators environmental air emissions ozone depleting substances waste organisations socially responsible investors management sites generally weakest biodiversity risk assessment selfauditing selfaudit nevertheless panel met first time september achieved one biggest improvements year review draft position papers pharmaceuticals along process risk management environment climate change policy use chemicals issues identified important previous gsk corporate responsibility report environment continued stakeholder discussions members wanted us show biodiversity effectively audit programmes leadership three issues provide better sponsored policy group green alliance explanation papers fit ehs conduct study achieve better environmental strategy comments considered internal regulation discussions finalised position papers conscious stakeholder engagement approved corporate executive team activities heavily focused uk begun position papers available via relevant explore ways extend europe us sections site beyond next years panel also reviewed proposal revising ehs many sites also engage stakeholders locally plan excellence members expressed desire see us example open days newsletters forefront ehs sustainability issues exerting community projects positive influence others industry supply chain comments see side panel considered regulation developing plan gsk keen see proper measures place protect environment safeguard development launch internal engagement new medicines engaged regulatory regularly gather staff feedback employee agencies europe usa issues surveys used intranet conduct pharmaceuticals environment pie extensive survey yet views employees environmental risk assessment pharmaceuticals ehs plans feedback also used revise develop plan excellence us engaged newly established intergovernmental task force pie trade employees told us association phrma ehs strategy must add value gsks business active member association british well right thing pharmaceutical industries working group pie employees want gsk among top liaising uk environment agency pharmaceutical companies ehs collaborate sweden participated initiative organised major players industry trade association lif develop voluntary scheme need embed ehs business classify pharmaceuticals environmental systems instilling culture employees effects scheme published see contribute ehs httpwwwfassse initial set pharmaceuticals evaluated gsk champion transparency ehs european trade association efpia track influence new contributed development guidelines regulations involvement trade environmental risk assessment pharmaceuticals associations european medicines evaluation agency emea need address ehs issues contract guidelines expected finalised manufacturing welcome introduction formal requirements plan excellence must flexible enough conduct environmental risk assessment established allow different rates progress different parts eus new medicines legislation gsk lobbied business environmental impacts pharmaceuticals partnerships regulated solely european agency also partner number environmental evaluation medical products also organisations specific areas example proposed framework registration evaluation worked forum future evaluate role authorisation chemicals reach believe pharmaceutical company sustainable society would lead duplication efforts place also worked environmental organisation unnecessary burden pharmaceutical industry earthwatch institute europe look ways address gsk corporate responsibility report environment continued training awareness awareness raising employees awareness environment health use several means raising awareness ehs issues safety issues improving skills complementing training programmes training key parts ehs programme employees chief executive officers ehs excellence awards levels need understand ehs issues scheme recognises outstanding efforts ehs helps working environment example employees raise profile issues around business handle waste gsk sites need know properties regulations govern disposal publish regular bulletins distributed materials recycled sites posting bulletin boards three bulletins circulated help employees deal issues include articles ehs internal magazine meetings bulletins information intranet site gsk spirit manufacturing magazine site well specific training events newsletters intranet site myehs community contains links run environment week every june coincide range programmes including ehs manager world environment day information kits information system contains policies standards sent sites help develop ideas plan guidelines tools training materials examples best activities gsk employees practice news also provides customised sites worldwide took part environment management reports ehs performance site week activities focused issues varied ehs training also accessible mylearning biodiversity sustainable purchasing waste gsk 's online training service management training also encourage employees consider environmental training takes place site level accordance issues outside workplace minimizing ehs standard training ehs requirements household waste energy water conservation programmes routinely included site induction encouraging use fuelefficient vehicles training new employees regularly assess additional needs make sure match employee responsibilities ehs excellence awards local regulatory requirements chief executive officers ehs excellence awards recognise reward gsk sites innovation ehs carried additional ehs management community partnership green chemistrytechnology training consumer healthcare regional ehs initiative one environment one health pharma supply organisations made site visits safety winner receives trophy selects oneonone training sent ehs essentials cdbased charity receive donation gsk compliance tool sales offices around world improve ehs awareness vanguard award introduced given discretion ceo honour recurring lasting held regional meetings uk far reaching accomplishments ehs mexico china spain ehs employee health professionals share information best practice fourth year awards employees sites took part entries countries meetings included training ehs management system applications gsks business sectors auditing auditing hazardous waste disposal sites injury rd manufacturing commercial first illness reporting ergonomic risk assessment resilience time entries facilities management teams mental wellbeing winners chosen panel included experts ehs managers encouraged attend conferences academia government ngos training programs sponsored local environmental projects representing sites europe north america organisations academic institutions asia received top honours winning projects covered areas diverse safe driving programmes new product processes use less energy reduce waste gsk corporate responsibility report environment continued award winners new manufacturing process diabetes drug reduced number stages required synthesis vanguard award increasing yields reducing waste rajahmundry india received first ever vanguard avoiding use hazardous materials award recurring lasting far reaching accomplishments ehs third placetonbridge united kingdom development environmentally friendly process rajahmundry horlicks related products manufacture gwf made outstanding record ehs excellence awards received two first place awards tonbridge developed new process synthesising one second place awarded special potential asthma drug using cheap readily available commendation year received another materials reduce health safety concerns first place ehs initiative category first rate amount solvent required manufacturing ehs community partnership entry demonstrated ehs initiative environment continuing passion building good relationships first place rajahmundry india use methane gsk local community though imaginative environment health safety partnerships waste management review revealed also became first gsk site achieve methane generated rajahmundrys effluent accreditation international standard social treatment plant burnt flare stack ehs accountability sa following iso ohsas team diverted methane use fuel site accreditation environment health safety canteen instead liquefied petroleum gas community partnership second placerixensart wavre belgium first placearanda spain supporting implementation management green spaces agenda schools rixensart wavre sites belgium teams agenda emerged earth summit rio de develop manage green spaces developed janeiro plan sustainable development number short medium term projects protect aranda contributed introduction eight natural environment improve biodiversity schools local community promoting environmental around sites education third placethane india water conservation second placenabha india ignited minds building site carried water conservation project awareness road safety included raising employee awareness focused project aimed raise childrens awareness safe three initiatives harvesting rainwater reuse driving road safety five government schools introducing water saving recovery measures nabha reaching total children sites heating cooling systems recycling treated effluent water gardening green chemistrytechnology first placetonbridge united kingdom development green process gwa new manufacturing process antiretroviral drug gwa significant environmental benefits well cost savings produces solid waste sent landfill reduces liquid waste uses less energy second placeresearch triangle park united states america development manufacture route gwx gsk corporate responsibility report environment continued progress towards targets wastewater quality measured chemical oxygen demand ehs plan excellence identified targets areas interim targets halfway plan nonhazardous waste disposed period review progress five target nearly achieved years well beginning work extend plan five years volatile organic compounds emitted air achieved six targets missed four targets achieved ozone depletion potential ancillary equipment targets achieved hazardous waste disposed energy use waste recycled global warming potential energy use chart summarises progress since ozone depletion potential production inhalers comparison targets per unit sales water consumption targets achieved targets per unit sales compared baseline performance target energy warming odp duction water cod azardous waste bal pro nh gl n targets achieved performance target energy consumption global warming energy ozone depletion potential production water consumption chemical oxygen demand wastewater nonhazardous waste disposed tnemevorpmi gsk corporate responsibility report environment continued targets achieved targets per unit sales compared baseline performance target e voc ancillar us wast recycle p e od zard wast h targets achieved performance target volatile organic compound emissions air ozone depletion potential ancillary equipment hazardous waste disposed waste recycled tnemevorpmi gsk corporate responsibility report environment continued performance affected significant business materials efficiency changes outsourcing reduced improving efficiency convert raw water consumption improved wastewater quality materials finished product important objective cases solvent recovery product transfers environmental sustainability help us reduce new product introductions made difficult consumption natural resources waste generation achieve targets cost production believe able met targets energy consumed double material efficiency new processes associated global warming potential largely due coming rd chemical development achieving significant improvements energy savings primary material efficiencies active pharmaceutical ingredient manufacturing plants research development ie tonnes active pharmaceutical ingredient used energy due increased activity every tonnes input chemicals new processes propose target new missed targets recycling disposal year plan hazardous waste fourfifths solvent performance affected complex mixture efforts supported us drug regulator factors one hand food drug administration fda fda focussing process technologies recommends phaseout older products years pharmaceutical manufacturers increase focus steps contributed reduction solvent manufacturing processes waste pharmaceutical industry tended use much new products made tend fewer raw material every kilo finished product manufacturing steps old products means process sectors agrochemicals fine less solvent energy used chemicals industries pharmaceutical processes typically sites modified equipment recycle solvents complex usually involving many separate operations received processes moved often requiring relatively large amounts solvent facilities previous years typically industry uses kg material however every kilogram active pharmaceutical ingredient produced material efficiency compares new products mean pilot plants running fine chemicals bulk chemicals manufacturing plants take time adjust represents waste valuable resources financial solvent recycling operations new solvents well environmental consequences gsk aims take time adjust solvent recovery make improvements future operations new products approach addressing ehs issues already includes one case site needed refurbish solvent minimising amount material used flasc green recovery equipment dispose solvent chemistry tool see product design includes mass would ordinarily recovered reused material used part lifecycle assessment plan next years interim targets material impacts chemical development scientists construction link plan targets especially quality issues minimising aligned gsk business drivers state timescale developing manufacturing process aspirations move towards environmental sustainability may conflict improved material efficiency consulted internally externally plan begun placing higher priority improving ensure reasonable reflects measures use materials bringing together rd drive positive practices businesses align manufacturing teams increase focus material stakeholders expectations extensive consultation efficiency product development stage well means full plan ready publication selected existing products use two key measures least mid production efficiency full details performance shown section mass productivity mass materials used report process compared mass product produced gsk corporate responsibility report environment continued reaction mass efficiency rme gives measure case study efficiency putting together key building blocks drug molecule excluding large material efficiency tonbridge volumes solvents normally used gsks research development site tonbridge uk medium chemical reactions materials dramatically improved material efficiency essential reaction process developing robust manufacturing process already making dramatic improvements antiretroviral compound treating hiv materials efficiency example rd team tonbridge uk increased production mass efficiency original process required substantial energy production antiretroviral drug manufacturing dealing waste also used chart shows substantial efficiency improvements hazardous solvent dimethylformamide acid development phase several new compounds methanesulfonic final process based examples demonstrate potential chemistry use hazardous improvement although scale improvement materials achieved processes aim build new process increased mass efficiency successes rd manufacturing ehs plan increase tonbridge excellence include improvement target material team identified effective reagents may efficiency products emerging rd also potential substitutes gsk processes process requires less energy original route cycle time shorter uses lower processing temperatures reduction contaminated aqueous waste also results significant energy savings waste requires energy intensive incineration tonbridge estimates new process requires twothirds incineration energy waste disposal peak production rates could avoid kg carbon dioxide emissions year equivalent driving average family car two million miles tonbridge first place green chemistrytechnology section ehs excellence awards work process gsk corporate responsibility report environment continued graph showing rd process development reduces amount material needed manufacture drugs initial process mass intensity represents number kilograms material produce one kg product ytisnetni ssam developed process drug drug drug drug gsk corporate responsibility report environment continued product stewardship toolkit address environmental issues associated ecodesign toolkit used rd manufacturing products throughout life cycle begins scientists engineers highlight potential ehs issues product design continues managing early development process practicable impacts manufacturing operations including toolkit currently five modules four contract manufacturing eventual disposal refer significantly revised make easier product stewardship use continue updated appropriate added guide hazardous chemicals section focuses legislation product design incorporating toolkit available gsk intranet consists environment health safety considerations design new products green chemistrytechnology guide helps pharmaceuticals environment gsk scientists engineers apply green chemistry understand minimise impact concepts achieve efficient use resources pharmaceuticals released environment use reduce environment health safety impacts specific issues metered dose inhalers minimise costs reduce ehs impacts progressing target eliminate use materials guides containing information range cfcs ozone depleting gas product materials used within gsk operations including portfolio solvents avoided one guide covers see environmental issues solvent selection second deals chemical associated products corporate base selection responsibility website including use genetically green packaging guide assessment tool modified organisms use natural resources includes guidance business process evaluating potential impacts biodiversity research selecting packaging options pharmaceuticals development section report covers approach consumer healthcare businesses animal testing flascfast lifecycle assessment synthetic product design chemistry webbased tool process launched working incorporate environment health allows bench chemists perform safety considerations design new products streamlined lifecycle evaluation environmental ehs staff participation support new impacts new existing processes based product teams use ecodesign materials used flasc helps scientists managers toolkit rapidly identify greenest materials option comparing benchmarking processes routes continued integrate ehs milestone make gsk products identifies materials aligned process map product development significant lifecycle environmental impacts supply processes including rd design provides guidance reduce impacts manufacture initiative rd manufacturing staff trained past chemicals legislation guide clgis two years ehs map process newest product stewardship tool identifies chemicals legislation various parts world aimed ehs involvement new product teams also provides phasing hazardous substances routine use unique opportunity influence supply chain decisions clg incorporates hazard information volume highlight systemic ehs issues early product phase use provide riskbased guidance development process involvement teams variety chemicals concern form easy responsible products move rd scientists use manufacturing also means residual ehs risks identified managed appropriately module designed ensure ehs impacts manufacturing materials processes services considered manufacture raw materials ultimate fate products wastes environment gsk corporate responsibility report environment continued working key rd extensive internal consultation paper approved groups make ecodesign toolkit compelling december useful rd manufacturing scientists engaged us interagency task force engineers pharmaceuticals environment uk pharmaceuticals environment environment agency phrma association drugs work active pharmaceutical ingredients british pharmaceutical industry respectively absorbed patients body materials interacting governmental groups working including anything absorbed eventually area us environmental protection agency excreted bodys normal mechanisms us geological survey establishing enter sewage system wastewater treatment plants relationships groups working issue europe remove pharmaceutical residues small gsk scientists part team experts concentrations end rivers sea areas international scientific workshop human without wastewater treatment higher concentrations pharmaceuticals environment coauthored enter environment number chapters book human pharmaceuticals pharmaceuticals detected surface ground assessing impacts aquatic ecosystems published drinking waters us europe raised work provides roadmap industry concerns potential impacts people animals government academia research area environment eg contributing antibiotic resistance worked phrma develop database feminisation oestrogens effects highly potent scientific literature impacts pharmaceuticals drugs environmental organisms presence anti aquatic life also collaborated prepare detailed depressants drinking water effects wildlife human health environmental risk assessments veterinary drugs pain killers regulators several frequentlydetected pharmaceuticals acting concerns example swedish carbamazepine aspirin paracetamol ibuprofen authorities require additional information classify naproxen work part ongoing phrma research pharmaceuticals environmental impacts european improve understanding provide data needed union proposing extensive environmental testing prioritize investigation product registrations others investigating mitigation measures takeback schemes water continued comprehensive environmental risk treatment upgrades labelling revisions assessments using phate model us greater model europe active gsk developed business processes ensure pharmaceutical ingredients developed allowable daily carry appropriate environmental tests environmental intake levels human consumption drinking risk assessments part approval process new water fish consumption well noeffects levels drugs eu us provide regulatory agencies aquatic organisms make quantitative risk assessments evaluate allow mitigation assessments comparing predicted potential environmental impacts environmental concentrations also work pharmaceutical companies assessments published website universities research groups develop science peerreviewed scientific literature methodologies assess environmental risks underlying environmental fate effects test data pharmaceuticals environment increase pharmaceutically active components gskmarketed understanding risks example us products embedded safety data sheets gsk involved pharmaceutical research sds available website wwwmsds manufacturers america phrma developing gskcom phate pharmaceutical assessment transport evaluation model based specific local hydrology risk assessments carried date indicate population patterns products appear pose appreciable risk humans environment based current methods action ascertaining effect levels continue monitor finalised position paper pharmaceuticals latest scientific studies findings improve risk environment developed assessments area gsk corporate responsibility report environment continued metered dose inhalers montreal protocol bans production cfcs metered dose inhalers mdis used deliver main exempts number essential uses include forms treatment asthma sufferers mdis nevertheless plan eliminate use cfcs pressurised handheld devices use propellants worldwide product portfolio deliver doses medication patients lungs committed stop making cfc devices developed first introduced cfcs traditionally country markets end used propellant nontoxic non request essential use cfc allocation us reactive nonflammable odour eu taste offer selection alternatives countries patient uses mdi propellant released main alternative propellant use hfc atmosphere thousand kilograms affect ozone high global cfc propellant released patients used warming potential products eu us data also invested heavily dry powder delivery rest world much smaller proportion cfcs systems use cfcs hfcs estimate thousand kilograms escaped air production invested million billion inhalers worldwide see ozone depleting substances new plant rd cfcalternatives since identified issue ozone depletion potential patient use metered dose inhalers tnelaviuqe cfc gk noillim ozone depletion potential patient use metered dose inhalers year odp note ozone depletion potential charts report ozone depletion potential cfc equivalents defined united nations environment programme unep ozone secretariat data include eu us gsk corporate responsibility report environment continued energy global warming potential note global warming charts increase greenhouse gases atmosphere global warming impact energy calculated thought many scientists causing rise using conversion factors world business earths temperature known global warming burning council sustainable development wbcsdworld fossil fuels heat power releases carbon dioxide resources initiative wri greenhouse gas protocol co significant greenhouse gas initiative september stationary mobile set target reduce global combustion workbooks intergovernmental warming potential energy per unit sales panel climate change met target achieved reduction use conversion factors uk department per unit sales report energy section environment food rural affairs calculate gsks global warming impact comes mainly co business air travel air freight energy used facilities manufacturing rd investigate assess use updated office sites accounts twothirds carbon conversion factors energy beginning dioxide emissions concentrating efforts reduce emissions although also working energy use facilitiesincludes energy emissions transport compounds use consumed gsk facilities form electricity products steam purchased fuels burned fixed combustion equipment site including emergency generators use compounds contribute global warming figures include fuels used generate steam producing metered dose inhalers ancillary electricity onsite fuel onsite transport equipment compounds contribute global energy consumption section report includes warming also released patients use metered breakdown energy data dose inhalers include cfcs hcfcs also deplete ozone layer hfcs report emissions transportincludes business travel air including ozone depleting compounds ozone depletion transatlantic flights us uk flights section see also product stewardship within eu us routine business activities use ozone depleting compounds products flights originating uk large group events sales conventions business travel road including carbon dioxide methane waste treatment companyowned vehicle fleets primarily global sales fermentation also account global warming fleet product freight air increase global impact warming potential transport since mainly continue working minimise energy use improved reporting systems emissions face significant challenges expected comprehensively collect transport data growth new products require additional equipment example data include business air require additional energy work travel within eu us include uk balance growth continuing find opportunities international sales fleet travel greater efficiencies new existing facilities data include employee travel work operations result expect energy use related collect data flights originating us co emissions reduce per unit sales year large group events modes business travel including rail bus calculate co performance emissions road rail sea freight transport global warming potential decreased central data collection system robust compared since areas impacts small compared air freight transport transport section report includes breakdown transport data ozone depletion data include cfcs released patients use metered dose inhalers otheris co equivalents waste treatment fermentation gsk corporate responsibility report environment continued global warming potential tnelaviuqe oc gk noillim operations energy transport energy compounds global warming potential year operations transport compounds total compounds contribute global warming includes waste treatment fermentation gsk corporate responsibility report environment continued energy consumption emissions trading energy use facilities accounts twothirds number uk sites participate government 's gsks global energy consumption used emissions trading scheme ets helping us gain million gigajoules energy produced emissions experience carbon trading uk ets voluntary million kg co bought energy scheme rewards companies lower energy taxes electricity small amount municipal improve energy efficiency sites keep emissions steam hot water generated rest sites agreed target bank spare credits help comply limits subsequent years consulted inside outside company sell credits participants scheme position statement future use energy achieved required emissions target year drafted response stakeholder feedback course next target year energy use impact global warming key concerns draft position sets strategy energy european union trading scheme came force efficiency renewable energy emissions trading start first phase runs sites greater megawatts installed continued work energy efficiency initiatives combustion capacity required participate total demonstrated following site projects gsk sites regulated scheme stevenage uk installed solarpowered street lights performance verified external auditors although sites exceeded cap port fairy australia assessed wind turbine anticipate overall surplus carbon bioenergy potential credits scheme plan bank nashik india installed solar heating canteen hot credits help us comply future limits expect water trade remainder credits research triangle park us increased sponsorship performance level state green power programme energy consumption excluding transport add kwh renewable energy total energy consumption increased north carolina 's power supply decreased since energy zebulon us saved energy better control consumption per unit sales decreased laboratory lighting introducing motionactivated since met lighting reducing temperature office target reduction per unit sales since buildings degrees global manufacturing supply gms research us pharma rd site operations created development rd greatest impact gsks strategic energy leadership council bring together energy consumption profile account managers common interest energy gsks energy consumption respectively management provide leadership energy matters rd used almost energy expanding council implemented energy utilities products move rd pipeline initiatives saved excess million partially offset energy efficiency initiatives keep including energy conservation tracking database increase energy use minimum energy managers energy technology workshops working projects improve energy efficiency suzhou china modified chilled water system expanded activity require equivalent avoid using chiller air temperature increase energy use low enough ensure cool water saved primary supply antibiotics group within gms estimated kwh electricity year reduced total energy use third since greatest reduction gsk supply group operation time period significant reduction result focus energy efficiency coordinated effort identify implement site specific programmes sites supply group gsk corporate responsibility report environment continued energy consumption excluding transport seluojagig noillim target per unit sales percentage baseline rh axis nontransport fuels electricity purchased steam purchased energy consumption excluding transport year steam electric nontransport fuels total gsk corporate responsibility report environment continued energy consumption business excluding transport primary supply antibiotics commercial biologicals regional pharma supply new product global supply research development consumer healthcare supply primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total million gigajoules gsk corporate responsibility report environment continued global warming potential energy case study total global warming potential energy use facilities increased less saving energy using waste methane decreased since global warming potential gsk 's consumer healthcare site rajahmundry per unit sales decreased since since india captured methane generated anaerobic meaning met target digestion wastewater sludge previously reduction per unit sales since wasted uses instead liquefied petroleum sulphur dioxide nitrogen oxides gas lpg site canteen use methane kilograms nox kilograms correct double cap project completed emitted sites coalfired power march reduced risk storing lpg cylinders well conserving resources saving money eliminating waste note energy charts methane generated factorys effluent energy consumption facilities defined treatment plant previously majority highly energy consumed form electricity steam flammable gas burnt flare stack purchased fuels burned fixed combustion used production distilled water use equipment site including emergency generators methane project examined gas could put figures include fuels used generate steam productive use identified canteen fuel electricity onsite fuel onsite transport best solution global warming potential energy use factory laid pipeline anaerobic digestion facilities calculated using conversion factors canteen bought new stoves adapted world business council sustainable development burn methane rather lpg wbcsd world resources initiative wri greenhouse gas protocol initiative september stationary project reduced amount lpg used mobile combustion workbooks sites canteen saving cylinders gas intergovernmental panel climate change year worth storing fewer lpg cylinders also improved safety significantly reducing nox calculated coal used risk explosion two gsk facilitiesin india use coal using conversion factors national atmospheric use methane awarded first place ehs emissions inventory uk national methodology initiative environment category ceo 's ehs excellence awards gsk corporate responsibility report environment continued global warming potential energy excluding transport tnelaviuqe oc gk noillim target per unit sales percentage baseline rh axis nontransport fuels electricity purchased steam purchased global warming potential energy excluding transport year steam electric nontransport fuels total gsk corporate responsibility report environment continued global warming potential energy excluding transport business biologicals research development commercial new product global supply regional pharma supply consumer healthcare supply primary supply antibiotics primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total million kg co equivalent gsk corporate responsibility report environment continued transport encourage employees use video estimate transport accounts teleconferencing possible reduce air travel total global warming impact emitted virtual meeting software available employees approximately million kilograms co making presentations collaborative working transport average gsk employees conduct video meetings teleconferences virtual meetings per business air travel accounts almost half month travelrelated co emissions employees travelled total almost million kilometres plane performance decrease since resulting million total global warming potential transport increased kg co emissions includes transatlantic flights since increase since us uk flights within eu us mainly improved reporting routine business activities well travel originating systems collect comprehensive transport data uk related large group events sales example data include business air conventions travel within eu us include uk international sales fleets believe still global sales fleet drove total underestimating global warming potential million kilometres business travel resulting transport robust system million kg co collect group air travel originating uk addition business travel also transport products manufacturing plants distributors gsk products transported total million note transport chart kilometres majority air freight data business air travel includes transatlantic flights estimate air freight resulted million kg us uk flights within eu us co increase due routine business activities flights originating improved data collection uk large group events sales conventions continued business growth data business travel road primarily global sales fleet collect data modes increased sourcing china business travel including rail bus rise clinical trials conducted outside us uk co air freight covers global routes launched number initiatives reduce calculate co emissions road rail sea impact transporting products include freight transport central data collection consolidating freight shipments pharmaceutical system robust areas impacts consumer products transported together consolidating small compared air freight shipping points making use round tripping transport managing inbound freight trucks return empty also convert air transport sea transport use conversion factors uk department possible environment food rural affairs calculate co business air travel air freight green travel plans number sites encourage employees reduce environmental impact travel work example gsk house brentford uk privileged parking spaces given car sharers drivers fuel efficient cars buses run local train station changing rooms showers provided cyclists well discounts bicycle equipment repairs gsk corporate responsibility report environment continued global warming potential transport business travel road business travel air product freight air tnelaviuqe oc gk noillim global warming potential transport year freight business air business road total gsk corporate responsibility report environment continued water case study water valuable natural resource needs conserved protected pollution water water conservation thasne india conservation particularly important areas gsks site thane near mumbai india water shortages common manufactures medicines local market thane gsk uses water manufacturing eg processes introduced measures conserve minimise water products cooling cleaning general site use including rainwater harvesting improving uses including drinking food services sanitation efficiency installing water saving technologies amount water sites use varies according site reduced water activities take place primary supply sites consumption kilolitres per year manufacture active pharmaceutical ingredients kilolitres per year typically heavy users water sites site located monsoon region meaning manufacture vaccines produce drinks involved experiences irregular rainfall water shortages research development commercial sites dry season problem amplified typically use less increasing urbanisation agricultural development gsk water standard requires sites minimise water thane receives water municipal supply use reuse water whenever feasible sites required uses cooling generating steam boiler minimise potential environmental impacts gardens discharging wastewater thane installed rainwater catchment devices roofs water use near sites boiler cooling towers rainwater pumped storage tanks ready immediate use used million cubic metres water pumped borewell replenish water average industry based benchmarking table result water consumption peak major pharmaceutical companies source monsoon month september dropped water mainly municipal water supplies wells kilolitres kilolitres boreholes small amount sources several measures introduced save water including steam recovery device boiler total water consumption increased less since prohibiting hose cleaning plant floors installing since water consumption photosensors urinals installing foot per unit sales decreased since since operated taps sites canteen means met target cut water use per unit sales mainly due consolidating thane installed drip irrigation system garden primary manufacturing sites following merger sprinkler system changed reduce outsourcing fermentation processes amount water lost evaporation changes garden included altering planting introduced water conservation measures season coincide wetter months watering plants example site thane india one early morning allowing grass ceo 's ehs excellence awards water conservation grow longer holds soil moisture measures see similar projects submitted sites pakistan india indonesia poland canada thane awarded third place environment category ceo 's ehs excellence awards note water use charts water conservation improvements water use includes water sourced wellsboreholes municipal sources mainly wastewater external industrial sources data include water used manufacturing processes general sites uses well water incorporated products gsk corporate responsibility report environment continued water consumption water consumption year wellsboreholes municipal total mainly wastewater external industrial sources sertem cibuc noillim target per unit sales percentage baseline rh axis wellsboreholes municipal sources gsk corporate responsibility report environment continued water consumption business commercial primary supply antibiotics biologicals new product global supply research development regional pharma supply consumer healthcare supply primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total million cubic metres gsk corporate responsibility report environment continued wastewater note wastewater cod charts generated million cubic metres wastewater volume includes manufacturing site wastewater manufacturing processes various process wastewater well sanitary food service site operations less since wastewater decrease mainly due consolidating primary manufacturing sites following merger wastewater quality measured chemical oxygen outsourcing fermentation processes demand cod measure oxygen reused recovered recycled total wastewater required chemically oxidise organic inorganic compounds present water gsks ehs standards require sites reuse water whenever feasible ensure wastewater cod measured wastewater leaves treated discharged way minimises adverse sites following onsite treatment environmental impacts sites discharge wastewater municipal treatment facilities either without prior treatment large sites especially primary manufacturing sites onsite wastewater treatment systems sites permitted discharge wastewater direct sea five sites india implemented zero wastewater discharge programmes reusing recycling wastewater use processed wastewater watering plants trees help provide shade improve appearance site also source food employees discharge wastewater water bodies municipal sewers site xochimilco mexico uses processed wastewater watering gardens around site washing vehicles windows uses requiring drinking water sites turkey philippines also reuse wastewater assess quality wastewater measuring chemical oxygen demand cod oxygen required chemically oxidise organic inorganic compounds present water lower cod cleaner water total cod decreased compared since reduction due site ulverston uk outsourcing fermentation processes cod per unit sales decreased since since meaning achieved target reduction per unit sales since gsk corporate responsibility report environment continued wastewater volume wastewater volume year sea estuary sewer total includes direct river reusedrecoveredrecycled sertem cibuc noillim direct sea direct estuary municipal sewer gsk corporate responsibility report environment continued wastewater volume business commercial new product global supply primary supply antibiotics regional pharma supply biologicals research development consumer healthcare supply primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total million cubic metres gsk corporate responsibility report environment continued wastewater chemical oxygen demand gk noillim target per unit sales percentage baseline rh axis direct sea direct estuary municipal sewer wastewater chemical oxygen demand year sea estuary sewer total includes reusedrecoveredrecycled onsite irrigation gsk corporate responsibility report environment continued wastewater chemical oxygen demand business research development new product global supply biologicals regional pharma supply primary supply antibiotics consumer healthcare supply primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total million kg gsk corporate responsibility report environment continued waste gsk heritage companies spent cleaning sites us research production commercial activities last years continuing clean produce waste aim manage safely sites waste disposal sites gsk responsibly manage waste generated one several responsible parties final disposal want eliminate waste reduce reuse materials continue work reducing waste especially possible recycle waste dispose remaining hazardous waste one material efficiency material sensitively aspirations minimise number solvents used use smaller amounts dont much dispose generate different kinds waste different parts operational excellence initiative started business strong focus elimination types production hazardous wastes solvents waste manufacturing processes reflected chemicals applications ceo 's ehs excellence awards rd quality laboratories small amounts projects involved eliminating recycling waste chemicals including products intermediates well performance waste covered following broken glassware plastics pages offices paper standard commercial waste hazardous waste renovations take place production office lab hazardous waste consists space produce nonroutine waste solvents used production processes also obsolete equipment office furniture structural dispose lubricants fluorescent lights materials research waste includes animal carcases labs generate active ingredients pharmaceutical small quantities radioactive waste highly products manufactured using chemical processes regulated means significant proportion waste regulations vary widely around world first classified hazardous contains solvents choice solvents reuse recycle material chemicals used processes report hazardous possible main disposal option solvents waste separate nonhazardous identify non incineration aim use incineration energy routine waste construction demolition rubble recovery wherever possible volumes depend building activity tend inconsistent main focus work improve material efficiency reduce total amount solvents use production facilities segregate wastes reuse send recycling disposed million kg hazardous waste incinerate landfill anything else incineration usually excluding demolition construction waste preferred choice dealing solvents cant mostly solvents rest general site waste reused recycled sites try use waste management chemical biological radioactive waste companies use incinerators recover energy hazardous waste disposed burning materials incinerated energy recovery incinerated aim use reputable waste handling companies without energy recovery remaining waste waste disposal require disposal contractors comply disposed licensed landfill sites ehs requirements local regulations internal ehs audit team audits waste disposal contractors make sure handle waste appropriately past waste chemicals handling practices longer followed contaminated land groundwater continuing clean sites deal health environmental hazards gsk corporate responsibility report environment continued performance note hazardous waste charts total hazardous waste disposed decreased since since hazardous waste although external definition constitutes disposed per unit sales decreased since waste varies gsk reporting purposes material increased since meaning meet considered waste longer fit originally target reduction per unit sales since intended purpose previous trend reducing hazardous waste per unit hazardous waste disposed includes disposal landfill sales reversed combination factors incineration either gsk property gsks hazardous waste mostly solvents one plant incineration energy recovery means burning scheduled closure dispose redundant solvent material using resulting energy incineration stocks one impact data addition without energy recovery means burning material changes production plants included bringing without using energy heat generated hazardous inhouse processes previously undertaken waste disposed include recycling onsite contract manufacturers moving existing processes offsite nonroutine waste among sites engineers continued assess consistent reporting gsk considers waste optimise new moved processes reduce solvent hazardous exhibits number properties use increase recycling resumed defined basel convention united downward trend nations environment programme unep included solvent recovery affected several factors properties flammability explosivity water air reactivity corrosivity oxidising potential acute repair solvent recovery equipment two chronic toxicity ecotoxicity infection addition sites resulted complete shutdown nature potential impact recovery operation commercial recovery operation research development activities radioactive wastes available solvent normally recovered defined hazardous bioengineered incinerated instead biohazardous waste included hazardous waste new products using new solvents continue come line take time sites gear solvent waste considered nonhazardous recovery recycling new materials exhibit hazardous properties noted pilot plants producing new products go clinical trials work wide range different solvents recycling practical primary sites difficulty handling solvents received result moving processes sites year sites began recover moves improved solvent recovery thereby decreasing amount solvents disposed one new site acquired contributed additional million kg total solvent recycled year gsk corporate responsibility report environment continued hazardous waste disposed gk noillim target per unit sales percentage baseline rh axis incinerated energy recovery incinerated without energy recovery landfill hazardous waste disposed year recovery without recovery landfill total gsk corporate responsibility report environment continued hazardous waste disposed business commercial consumer healthcare supply new product global supply regional pharma supply primary supply antibiotics biologicals research development primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total million kg gsk corporate responsibility report environment continued hazardous waste disposed sources gk noillim solvent waste site waste hazardous waste disposed sources year solvent site total includes chemicalbiologicalradioactivepharmaceutical waste gsk corporate responsibility report environment continued nonhazardous waste note nonhazardous waste charts nonhazardous waste general material although external definition constitutes office waste paper kitchen waste nonhazardous waste varies gsk reporting purposes material substances used manufacturing small part considered waste longer fit originally biological waste treated intended purpose hazardous include construction demolition rubble similar material related day nonhazardous waste disposal includes disposal today operations describe separately non landfill incineration either gsk property routine waste disposed million kg incineration energy recovery includes processes nonhazardous waste result beneficial energy resource recovery includes small amount composting incineration continue look ways reduce waste without energy recovery includes processes undertaken waste management reviews many sites result beneficial energy resource recovery non performance hazardous waste disposed include recycling total nonhazardous waste lower onsite offsite nonroutine waste lower weight disposed per unit biological waste rendered nonhazardous sales decreased year since treatment considered nonhazardous waste means considerably beaten target reduction per unit sales since gsk corporate responsibility report environment continued nonhazardous waste disposed gk noillim target per unit sales percentage baseline rh axis incinerated energy recovery incinerated without energy recovery landfill nonhazardous waste disposed year recovery without recovery landfill total gsk corporate responsibility report environment continued nonhazardous waste disposed business biologicals consumer healthcare supply commercial regional pharma supply new product global supply research development primary supply antibiotics primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total million kg gsk corporate responsibility report environment continued nonhazardous waste disposed sources gk noillim site waste nonhazardous waste disposed sources year site total gsk corporate responsibility report environment continued recycling recycle hazardous nonhazardous waste aiming minimise environmental impacts well cost materials waste largest waste component solvent used manufacturing process solvent purified sites reused original manufacturing process sometimes sell solvent commercial reprocessing companies also include recycling statistics solvent recycled way usually incinerated recycling nonhazardous waste glass plastic usually means sending reprocessing reused make new products performance recycled million kg waste nearly million kg waste generated twothirds total waste recycled hazardous waste primarily solvents proportion waste recycled higher decreased since mainly generated less waste means meet target increase proportion waste recycled since production changes last two years contributed incineration solvent waste recycled smaller proportion three large primary manufacturing sites back track recycling solvent reversed decline sites although continued difficulty recovery sites gsk corporate responsibility report environment continued proportion total waste recycled proportion total waste recycled year waste recycled target percentage baseline rh axis waste recycled gsk corporate responsibility report environment continued proportion total waste recycled business primary nu dp p al ny tibiotics ew product g la bd l supply egional pharma supply umer healthcare supply biologicals researc dh ea ven ld opment commercial n r n c proportion total waste recycled business primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial gsk corporate responsibility report environment continued total waste recycled gk noillim hazardous nonhazardous total waste recycled year hazardous nonhazardous total gsk corporate responsibility report environment continued nonroutine waste nonroutine waste primarily building materials site demolition construction activities small remediation projects disposed via landfill incineration million kg nonroutine waste recycled million kg performance amount waste fluctuates year depending plant upgrades site closures new building one vaccine plants accounted nearly half nonroutine waste rather sending waste landfill plant able provide excavated soil building expansion another company used clean fill note nonroutine waste charts although external definition constitutes waste varies gsk reporting purposes material considered waste longer fit originally intended purpose nonroutine waste disposal includes disposal landfill incineration either gsk property incineration energy recovery includes processes result beneficial energy resource recovery also recycle nonroutine waste whenever feasible gsk corporate responsibility report environment continued nonroutine waste gk noillim recycled incinerated energy recovery incinerated without energy recovery landfill nonroutine waste year recycled recovery without recovery landfill total gsk corporate responsibility report environment continued ozone depletion performance ozone layer essential human survival ozone depleting substances released ozone filters harmful ultraviolet uv rays sun production activities depletion ozone depleting substances odss include chlorofluorocarbons cfcs hydrochlorofluorocarbons substance kg factor potential hcfcs halons cfcr cfcs main odss use propellant gas cfcr metered dose inhalers mdi asthma sufferers cfc released patients use inhalers total ozone depletion potential production decreased thousand kilograms cfc propellant since since ozone depletion released patients used products eu potential production per unit sales decreased stopped making products us since since meaning information cfc releases patient use beaten target reduction per unit sales compiled outside eu required since regulation much smaller amount cfcs production cfccontaining mdis decreases thousand kilograms released worldwide amount cfc lost production also declines production offer selection alternatives longer manufacture cfccontaining mdis odscontaining inhalers countries plan us europe continue eliminate use odss product portfolio manufacture bangladesh china india see metered dose inhalers pakistan end also use odss cooling systems ancillary uses gsk facilities switched using hydrofluorocarbons hfcs cooling systems hfcs note ozone depletion potential charts deplete ozone layer contribute global report ozone depletion potential cfc warming ozone depletion potential ancillary use per equivalents defined united nations unit sales decreased since meaning environment programme unep ozone secretariat missed target completely eliminate emissions recognise way eliminate cfcs cooling systems new strategy focus installing new equipment achieve set new target eliminate cfc use line regulations based montreal protocol ozone depleting substances manufacturing small proportion cfc used propellant metered dose inhalers mdis released manufacturing process working eliminate use ozone depleting substances mdis switching hfc dry powder inhalers gsk corporate responsibility report environment continued ozone depletion potential production use tnelaviuqe cfc gk noillim target per unit sales percentage baseline rh axis production ozone depletion potential production use year production gsk corporate responsibility report environment continued ozone depletion potential production use business regional pharma supply new product global supply primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total thousand kg cfc equivalent gsk corporate responsibility report environment continued ozone depleting substances ancillary total ozone depletion potential ancillary increased equipment equipment replacement use ozone depleting substances odss primarily maintenance large site figure decreased cooling systems switched using since ozone depletion potential hydrofluorocarbons hfcs ancillary equipment ancillary use per unit sales increased since hfcs deplete ozone layer contribute decreased since global warming missed target eliminate ozone depleting odss mainly cfcs hcfcs sealed inside cooling emissions ancillary use proved possible systems released event leak eliminate emissions servicing maintenance maintenance cooling equipment means need upgrade replace equipment use nonozone closely monitor equipment put place depleting gases new cooling systems dont use recommendations alternative refrigerants new ozone depleting gases introduced equipment recognise way eliminate accordance regulatory requirements retrospect emissions eliminate cfc cooling systems believe target set unrealistic given new strategy focus replacing equipment potential improvement set new target eliminate cfc use line regulations performance note ozone depletion potential charts report ozone depletion potential cfc ozone depleting substances released ozone equivalents defined united nations ancillary activities depletion environment programme unep ozone secretariat substance kg factor potential cfcr cfcr hfcr hfcr r ra rafx rafx r methyl bromide gsk corporate responsibility report environment continued ozone depletion potential ancillary use tnelaviuqe cfc gk noillim target per unit sales percentage baseline rh axis ancillary ozone depletion potential ancillary use year ancilliary gsk corporate responsibility report environment continued ozone depletion potential ancillary use business biologicals consumer healthcare supply new product global supply research development commercial regional pharma supply primary supply antibiotics primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total thousand kg cfc equivalent gsk corporate responsibility report environment continued volatile organic compounds note voc charts use volatile organic compounds vocs mainly emissions volatile organic compounds vocs solvents primary manufacturing operations including fugitive sources evaporation released million kilograms vocs leaks measured gsk manufacturing operations atmosphere research development facilities vocs react nitrogen oxides presence vocs react nitrogen oxides presence sunlight creating ozone lower atmosphere sunlight creating ozone lower atmosphere results smog factor human respiratory results smog factor human respiratory illness workplace exposure certain vocs also pose illness report photochemical ozone creation health risk potential pocp ethylene equivalents conversion performance ethylene equivalents based european total vocs emitted air decreased chemical industry council cefic responsible care since vocs emitted air per unit sales decreased hse reporting guidelines vocs since since means missed target reduction per unit sales since achieved substantial reduction case study narrowly missed target reducing solvent use waste achieved reductions since due rationalising manufacturing operations following merger manufacturing expected set target decrease gsks rd site research triangle park us due site ulverston researching new drug treatment type ii outsourcing manufacturing improved data diabetes metabolic syndrome site collection also contributed developed new manufacturing process drug reduces waste solvent use eliminates photochemical ozone creation potential decreased use harmful substances since since previous manufacturing processes drug timeconsuming inefficient involving eight steps low production efficiency new process developed rtp number environmental health safety benefits process quicker involving three steps solvents needed aid synthesis step fewer steps mean less solvent required result amount solvent used voc emissions reduced amount waste produced also reduced importantly new process avoids use harmful alkylating agents hazardous rtp awarded second place green chemistrytechnology category ceo 's ehs excellence awards achievement gsk corporate responsibility report environment continued volatile organic compounds emitted air gk noillim target per unit sales percentage baseline rh axis voc volatile organic compounds emitted air year voc gsk corporate responsibility report environment continued volatile organic compounds emitted air business research development new product global supply primary supply antibiotics regional pharma supply primary supply antibiotics new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total million kg gsk corporate responsibility report environment continued photochemical ozone creation potential tnelaviuqe enelyhte gk noillim photochemical ozone creation potential year pocp gsk corporate responsibility report environment continued biodiversity biodiversity managed site level issues impacts local gsk sites required maintaining diversity plant animal species important part sustainability aim make identify assess potential impacts activities sure activities adversely affect biodiversity local habitats protecting local habitats wildlife improving sites act minimize adverse effects activities surroundings also part commitment local important habitats communities enhance biodiversity feasible wildlife threatened new site developments existing operations affect natural habitats monitor impacts ensure action remains effective habitats severely damaged depletion water protecting enhancing local biodiversity resources use water must particularly sensitive examples see water information water management nabha india developed biodiversity management investigation collection natural products plan develop ecoforestry acres land using also disruptive needs carefully managed water discharges site minimise adverse effects make limited use memphis tennessee us teamed natural products research happens north american butterfly association naba improve aim ensure investigation collection use habitat introduce species indigenous biological material purposes research adjacent president 's island manufacturing adversely affect biodiversity crawley uk worked specialist woodland contractors local wildlife trust enhance area case study working ribena suppliers improve crop field edges farm biodiversity drawn environmental action plan measures include trimming hedges less frequently gsk heritage companies making certain times year hedgerows green ribena years buy uks veins countryside providing food shelter blackcurrant crop growers many breeding sites many native species less frequent farmers family businesses supplying trimming every years allows hedges grow berries ribena generations produce fruit providing food birds bats small takes three years blackcurrant bush mammals insects farmers also leave uncultivated produces fruit big investment buy margins around fields protecting hedges directly grower agree seven year spraying adding bat bird boxes planting contracts helping plan ahead new trees blackcurrant farming mechanised berries joint projects growers include research shaken bushes harvesting machines rather uk department environment food picked hand enabled us reduce rural affairs increase vitamin c content number blackcurrant suppliers work ribena closely smaller group growers gsk helped establish blackcurrant growers group close relationship led farming meets quarterly share best practice environmental improvements one initiative blackcurrant foundation organisation promote partnership wildlife trust increase health environmental benefits blackcurrants biodiversity similar initiatives underway growers helped wildlife trust growers introducing new zealand supply blackcurrants ribena simple changes improve habitat animals sold asia gsk corporate responsibility report environment continued oak woodland site created pond sites scored based performance gsks thinned trees installed bird nesting boxes ehs standards key suppliers supplementary quantitative risk assessment scheme dartford uk supports partnership includes make recommendations following audit monitor uks environment agency working progress particular focus poorlyperforming safeguard historic dartford marshes vital suppliers safeguarding dartford flooding well supporting host rare protected species including water vole make significant improvements curtail end procurement sites meet minimal rixensart wavrenordin belgium close performance score ehs standards woodland working improving score unacceptable rating quantitative risk biodiversity several years planted assessment contract manufacturers minimum indigenous species shrub maximising use score increased flowering plants encourage bees insects requirement established orchards old varieties apples pears plums rixensart celebrated fifth supplier audits also cover basic questions human anniversary nature path employees created rights see human rights suppliers joined usepa green suppliers network suppliers gsn wwwepagovopptintrphomegsnprogramhtm green suppliers network programme help supply chain complex means assuring small mediumsized suppliers reduce ehs performance suppliers challenging environmental impact gsk supports programme currently provide oversight audit ehs issues initiatives undertaken operational centrally approximately critical suppliers excellence theme specific suppliers contract manufacturers materials used exclusively gsk based primarily europe supplier performance north america asia pacific carried sitebased ehs audits approximately half potentially new selecting negotiating managing key suppliers sites audited producers suppliers materials products manufacturing ingredients raw materials manufacturing supply chain take ehs lossprevention issues supply chain found wide variation performance account includes providing information scores ranging five suppliers ehs risks associated gsk materials determined unacceptable gsk 's audit producing handling assessment standards decided proceed carry ehs audits signing contracts suppliers significant improvements made significant new key suppliers contracts contain remaining audits sites supplying requirements based global ehs standards pharmaceutical consumer healthcare products subsequent ehs involvement based assessment materials research development performance ehs risks focussing ehs standards ranged threats continuity supply general suppliers based north america europe hazards associated manufacturing processes performed well performance asia pacific materials variable cases significant gaps ehs standards environmental impacts found apparent instances noncompliance regulatory requirements un universal declaration human rights core relevance supply essential medicines labour standards set international labour key suppliers present greatest risk gsk orgainsation ilo issues receive greatest scrutiny gsk corporate responsibility report environment continued reporting ehs performance ehs information collected possible selected suppliers data currently included ehs performance charts contained report subject verification erm requested information suppliers provided data provided data comparative figures suppliers produced total kg material resulting following energy use gigajoules water consumption cubic metres hazardous waste disposed kg nonhazardous waste disposed kg community investment introduction access medicine research ethical conduct employment practices human rights environment community investment value community investment humanitarian relief community partnerships supporting education employee involvement data summary gsk corporate responsibility report community investment gsk makes donations money medicines time equipment support good causes strategy behind community investment improving health education underserved communities support public health initiatives local community projects around world donate medicines support disaster relief efforts impoverished communities community investment linked shortterm awards business benefits intended create commercial markets gsk support reputation received first annual scrip award demonstrating commitment tackling healthcare corporate social responsibility gsks role challenges believe using profits lymphatic filariasis lf elimination programme benefit underserved communities part also received business community big tick responsible company uk science education programme support barretstown finalist number total community investment valued awards including million million equivalent pretax profits donations made group level business community international award individual gsk sites support local communities lf elimination programme objective ensure projects sustainable african investor award gsks support longterm continue gsk funding comes integrated management childhood end community investment made illnesses imci initiative africa nonprofit organisations experts us chamber commerce center corporate field healthcare delivery education helps citizenship award us education programme ensure giving targeted communities need information community investment programmes increase healthcare capacity developing countries value community investment included access medicines section report gsk donations valued million million covers major public health initiatives tackling compared million lymphatic filariasis lf hivaids malaria diarrhoea equivalent pretax profits related disease figure includes medicines worth million section provides information community million donated lowincome patients us investment programmes covers patient assistance programs million million breakdown charitable donations humanitarian product donations underserved communities around world million donations medicines humanitarian relief including million albendazole tablets lymphatic filariasis natural disasters elimination programme community partnerships local support provided total community investment also includes million corporate level gsk sites million cash grants almost million support science education us uk million management costs employee involvement communities gsk member uks percent club companies donate least pretax profits charitable causes gsk regularly one top companies uks guardian giving list lists ftse companies percentage pretax profits gsk corporate responsibility report community investment continued contributed charitable causes members uks london benchmarking listed th based percentage pretax group lbg committee encourage corporate profits donated fourth year philanthropy cecp us report donations row biggest overall giver value line guidelines set cecp values donations medicines wholesale acquisition cost line pharmaceutical companies wholesale acquisition cost wholesale list price including discounts method giving total cash product inkind management costs method giving million cash product inkind mangement costs breakdown cash giving total health education arts culture breakdown environment cash giving health education arts culture environment gsk corporate responsibility report community investment continued humanitarian relief following hurricane katrina donated medicines valued million relief facilities ten us states gsk donates essential products antibiotics help included antibiotics vaccines consumer healthcare relief efforts disaster areas support basic healthcare products toothpaste antacids pain relievers provision impoverished communities gsk also supplied interim shipments medicines donations made request governments diabetes heart disease asthma patients major charitable organisations may manufactured lost supplies disaster medicines specifically partners enables charities distributed hospitals shelters partner hold range medicines stock respond organisations project hope americares promptly emergency work partnership gsk largest pharmaceutical company pakistan several relief charities including americares direct relief able deliver urgent supplies free interchurch medical assistance map international medicines within hours earthquake via local project hope business product donations including hepatitis limit amount products give vaccines requested ministry health away donations must carefully managed rely valued million also gave cash donation expertise partners ensure available million south asia earthquake relief fund medicines targeted communities need gsk general managers must approve donations destined country avoid conflict community partnerships commercial business charity partners support wide range health education required track donations make sure reach initiatives communities operate intended destination dispensed appropriately donations made centrally gsk sites donate medicines diseases require support local charities good causes continuous assured supply examples many community gsk follows world health organization interagency partnerships supported guidelines drug donations state donations made response expressed need sent europe prior consent must labelled correctly barretstown ireland lenvol france residential minimum one year shelf life also member camps seriously ill children fun partnership quality medical donations pqmd develop self confidence gsk gave alliance pharmaceutical companies charities respectively encourages best practice donation delivery support camps employees also give time medicines barretstown lenvol gsk employees participating activity donated lifesaving medicines worth gsk also funding five european programmes million million support relief efforts almost grant three years countries supplies antibiotics basic medicines change advance disease prevention programme sent response south east asian tsunami promotes healthy eating exercise aimed hurricanes us caribbean slovakian children living urban housing estates earthquake pakistan childrens shelters programme spain provides immediate aftermath tsunami donated healthcare homeless abandoned children million doses antibiotics prevent beacon hope palliative care programme spread infectious diseases affected countries children romania also committed million million support organisations working relief reconstruction reading growing programme italy operations disaster area reading aloud helps children neuro functional disabilities endured long hospitalisation gsk corporate responsibility report community investment continued multi coloured lives interactive education across uk supporting parents carers young programme help children disabilities integrate babies children five dealing diagnosed russian society undiagnosed recurring chest problems international us gsks phase personal hygiene sanitation education gsk donating three years initiative providing education school arthur ashe institute urban health black children kenya uganda zambia nicaragua peru pearls programme provides health education low improve health hygiene fight infectious income neighbourhoods reaching nontraditional diseases committed threeyear funding venues including african american afrocaribbean extend programme bangladesh churches barber shops beauty salons laundromats partnership save children usa see major public tattoo parlours provides culturally appropriate health initiatives information help promote early disease detection encourage people multiethnic communities adopt gsk funding number country programmes healthier lifestyles grant three years continue support childrens health funds pinoy health pass family health well referral management initiative rmi new threeyear provides health education families low incomes grant million million help rmi continue philippines extend services philadelphia helping highrisk attituda positiva uses drama schools increase homeless children receive specialist medical care awareness education hiv reproductive need health teenagers brazil foundations midwives helps improve mother child health gsk operate single charitable foundation rural areas vietnam bringing birth attendants community investment programmes several ethnic minority groups training capitals countrybased foundations canada czech republic major hospital france italy romania spain north carolina uk us local foundations support wide range gsk supported charitable organisations charities healthcare initiatives uk included since gsk france foundation supported support medical research undertaken charities programmes countries focus people meningitis uk british liver trust alzheimers research living hivaids developing countries particularly trust samantha dickson research trust africa aim improve healthcare extended partnership british red cross prevention education training giving three years gateway project new programmes implemented countries scotland gateway helps young people disabilities grants euros gain skills selfconfidence need live gsk foundation canada focuses much independently since gateway worked support hospice care helping terminally ill patients small group young disabled people helping set families foundation also supporting personal goals receive individually tailored training community programmes africa including aids orphan support people disabilities also uganda threeyear programme building community visit centre year take part workshops support vulnerable children luweero district use facilities new funding enable gateway extend service across scotland share north carolina gsk foundation usa experiences health social care providers endowed selffunding organisation supports initiatives throughout uk areas mathematics science health education north carolina foundation awarded gsk giving two years grants totalling million million support british lung foundations baby breathe easy programme funding pilot scheme nine regions gsk corporate responsibility report community investment continued supporting education support sally ride science festivals aim increase girls interest science maths technology gsk supports education uk us festivals feature workshops led local particular emphasis developing scientific literacy veterinarians astronomers microbiologists encouraging next generation scientists engineers workshops also run parents science education uk teachers support girls interests gsk supporting inspire innovative scheme science technology careers postdoctoral researchers research education threeyear grant gsk scheme developed partnership imperial college helping national board professional teaching london specialist schools academies trust standards increase number science teachers million million donation four years north carolina philadelphia areas inspire aims raise achievement placing postdoctoral researchers specialist science schools train teachers support science teaching employee involvement fifth year gsk sponsorship grant gsk employees encouraged contribute association science education local communities volunteers supported science across world international hundreds employees give time good causes education programme enables school children days caring us support countries discuss science issues school science education uk science internet engineering ambassador scheme us partnership grant gsk uk science educational discovery teachers able participate active assessment uk us also make cash donations training helps teachers improve pupils charities employees done voluntary work thinking skills empowers take responsibility learning gsk investment volunteer excellence give programme gave gsk also committed million million four charitable organisations us employees years help build new darwin centre natural partners volunteered least hours history museum london enable better display year uk making difference programme museums important collection provided grants almost education us charities employees volunteered increased support initiatives many countries also encourage employees improve overall education standards us gsk donate money charity matching money founding partner us chamber commerces give providing taxefficient ways make business education network network develop donation accordance local taxation guidelines partnerships business community usa gsk matched donations education providers improve educational standards employees retirees value million bridge skills gaps million addition gsk gave million also continued support range science match donations gsk employees education initiatives annual gsk united way campaign science summer free librarybased education programme philadelphia giving children chance participate handson experiments science based courses gsk donated science summer enabled almost children participate almost children participated programme since launched nearly years ago gsk corporate responsibility report community investment continued case study gift life gsk product donations gsk antibiotics fight common lifethreatening infections donated antibiotics medicines worth million response disaster relief efforts travel packs medics humanitarian missions support healthcare provision impoverished communities threeyear old rosa angelica pravia one thousands people benefited admitted hospital remote part south america doctor feared infection could result meningitis father earns day cleaning pineapples children family could afford medicine treat fortunately hospital received donation medicines map international including gsks antibiotic ceftin within three days rosa danger doctor said ceftinhad saved life many products donated response specific requests relief charities americares direct relief interchurch medical assistance map international project hope map international uses donations gsk antibiotics augmentinand amoxilin travel packs medical missions packs compact fully stocked portable pharmacies enable teams treat wide range illnesses developing countries antibiotics treated many infections life threatening map team reported recently mission zambia local doctors told us go remote villages see patients resources fill prescriptions without gsks help would able see many patients help medication data summary introduction access medicine research ethical conduct employment practices human rights environment community investment data summary gsk corporate responsibility report data summary access medicines number countries supplied preferentially priced arvs number preferentially priced combivirtablets shipped millions number preferentially priced epivirtablets shipped millions gsk combivirnotforprofit price per day voluntary licences granted generic manufacturers gsk arvs number albendazole tablets donated prevention lymphatic filariasis millions number countries supplied albendazole research development gsk animal research facilities accredited association assessment accreditation laboratory animal care number trials published gsk clinical trial register cumulative total ethical conduct number employees completing certification gsk code conduct number contacts ethics compliance channels employment women management grades ethnic diversity people colour us ethnic diversity ethnic minorities uk lost time injury illness rate cases per hours worked lost time injury illness rate contractors working site cases per hours worked environment number contract manufacturers audited energy consumption million gigajoules water consumption million cubic metres ozone depletion potential metered dose inhalers tonnes cfc equivalent ozone depletion potential production tonnes cfc equivalent ozone depletion potential refrigeration ancillary uses tonnes cfc equivalent volatile organic compound emissions thousand tonnes global warming potential energy sources thousand tonnes co equivalent hazardous waste disposed thousand tonnes community investment total community investment expenditure millions value humanitarian product donations including albendazole millions value products donated gsk patient assistance program us millions includes arvs sold notforprofit discounted prices unable collect data number patients treated includes delivery costs mdecins sans frontires june report showed average cost generic equivalents day lowest priced generic equivalent costs day including delivery currently animal research laboratories animal research laboratories trials completed since merger created gsk includes contacts line managers compliance officers confidential integrity helplines offsite post office box us